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COUP-TFII AND ITS INTERACTING PROTEINS IN BREAST CANCER AND 
ENDOCRINE RESISTANCE 
Lacey M. Litchfield 
April 5, 2013 
Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) is an 
orphan nuclear receptor that functions as either a transcriptional activator or repressor. 
COUP-TFII expression is reduced in endocrine-resistant breast cancer cells and 
overexpression of COUP-TFII restores the ability of antiestrogens to inhibit cell 
proliferation. In this study, I tested the hypothesis that the activity of COUP-TFII in 
maintenance of endocrine sensitivity and cell differentiation is dependent on its 
interacting proteins. A direct interaction was identified between COUP-TFII and the 
phosphoprotein nucleolin, which was found to flIDction as a coregulator for COUP-TFII-
mediated transcription. COUP-TFII increased the expression of the tumor suppressor 
retinoic acid receptor B2 (RARB2) in a nucleolin-dependent manner. COUP-TFII and 
nucleolin expression were correlated in estrogen receptor a (ERa)+ invasive ductal 
carcinomas. COUP-TFII expression was inversely correlated with patient tumor grade. 
Aberrant activation of the NFKB pathway has also been implicated in endocrine 
resistance. COUP-TFII trans feet ion suppressed NFKB activity in endocrine-resistant 
breast cancer cells. COUP-TFII overexpression also reduced the expression of NFKB 
IV 
target genes (IL6, ICAMl, TNFAIP3, and CCL2) and subunits (NFKBl, REL, RELA, and 
RELB) through a mechanism involving interaction of COUP-TFII with NFK13 subunits 
RelB and NFK131 to inhibit NFK13 DNA-binding. COUP-TFII also reduced the ability of 
coactivators SRC-l, SRC-3, and CBP to enhance NFK13 activity. An inverse correlation 
between COUP-TFII and IL6, ICAMl, TNFAIP3, NFKB2, REL, RELA, and RELB was 
observed in breast tumors from tamoxifen-treated breast cancer patients. The 
combination of COUP-TFII overexpression, NFK13 inhibition, and tamoxifen treatment 
inhibited the growth of endocrine-resistant breast cancer cells . Endocrine-resistant breast 
cancer cells were more sensitive to treatment with an NFK13 inhibitor than endocrine-
sensitive cells, reflecting their reliance on the NFK13 pathway for survival. 
To further explore the role of COUP-TFII-interacting proteins III endocrine 
sensitivity, mass spectrometry was used to identify proteins that interacted with COUP-
TFII specifically when breast cancer cells were treated with tamoxifen versus vehicle 
control. HSP27 was selected for follow-up from the proteins identified as interacting 
specifically with COUP-TFII in cells treated with tamoxifen. HSP27 expression was 
reduced in an endocrine-resistant breast cancer cell line that has undergone epithelial to 
mesenchymal transition, L Y2, as well as in a trastuzumab-resistant breast cancer cell line, 
JIMT -1. A concomitant reduction in COUP-TFII expression was also observed in these 
cells. Future studies will explore the role of COUP-TFII-HSP27 interaction in resistance 
to tamoxifen and trastuzumab. COUP-TFII may be both a useful biomarker to predict 
tamoxifen and/or trastuzurnab sensitivity as well as a target to restore sensitivity to 
resistant cells. 
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CHAPTER I - BREAST CANCER AND ENDOCRINE RESISTANCE 
BREAST STRUCTURE AND DEVELOPMENT 
The complex branched stmcture of the adult mammary gland is composed of two 
basic cellular compartments: luminal and basal cells. Luminal epithelial cells line the 
lumen of the mammary duct, while the basal compartment is composed of progenitor 
cells and contractile myoepithelial cells that do not directly contact the ductal lumen. 
Coordinated paracrine signaling as well as stmctural connections between these two 
compartments are necessary for both the proper development and function of the 
mammary gland [1]. 
In the late 1950s, endocrine ablation experiments in rats and mice demonstrated 
that sequential timing of treatment with 1 7-~-estradiol (E2), progesterone, and prolactin, 
in the presence of cortisol and growth hormone, were the minimal hormones necessary 
for mammary gland development [1]. Sequential hormone excretion and/or hormone 
receptor expression is required for the formation of proper glandular stmcture. Estrogens 
mediate the beginning of ductal branching and elongation as well as initial side 
branching, followed by progesterone regulation of continued side branching and alveoli 
formation. Alveologenesis is completed by prolactin, which also regulates milk 
production during the late stages of pregnancy [1] . Milk is produced in the lobules and 
transported through the ductal system. The ducts and ductal-lobular units are extended 
during puberty and further expand during pregnancy and lactation [2]. Aberrant 
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proliferation can occur in both the duct and lobule structures to form ductal carcinoma or 
lobular carcinoma, respectively, although ductal carcinomas are more common, i.e., 75% 
of invasive breast cancers are ductal in origin, while 11 % are lobular (the remaining 14% 
comprise a heterogeneous set of less common classifications) [3]. 
BREAST CANCER SUBTYPES 
Breast cancer is the most commonly diagnosed cancer in women, and the leading 
cause of cancer death in females aged 20-59 years [4]. Breast cancers can be divided into 
5 basic SUbtypes based on their distinct gene expression data: normal breast-like, luminal 
A, luminal B, ERBB2+, and basal [5-7]. The luminal A and luminal B groups express a 
gene signature similar to that of the luminal epithelial cells of normal mammary tissue, 
while the basal subtype is more reminiscent of basal epithelial cells [6,7]. Luminal B is 
distinguished from luminal A by higher expression of the cell proliferation marker Ki67, 
a biomarker associated with recurrence, relapse, and overall worse outcome in breast 
cancer patients [8-11]. The ERBB2+ group is defined by overexpression of the 
HER2/neu (ERBB2) receptor, a member of the epidermal growth factor receptor (EGFR) 
family that is ligand-independent and constitutively active, a known oncogenic 
transformation associated with poor outcome in breast cancer patients [12]. Normal 
breast-like cancers express a gene signature similar to that of adipose tissue, basal 
epithelial cells, and other nonepithelial components of the breast [5,7]. Breast cancer 
SUbtype is also indicative of clinical outcome, with basal and ERBB2+ subtypes 
associated with a statistically significant decrease in survival [5,6]. Luminal A tumors 
2 
show the highest estrogen receptor a (ERa) expression of the five subtypes, while ERa-
cancers generally fall in the ERBB2+ or basal subtypes [6,7]. 
ESTROGEN RECEPTOR FUNCTION 
Estrogen' s action as the ovarian hormone responsible for maintenance of estrus 
was first characterized in 1923 by Allen and Doisy using partially purified hormone from 
the hog ovary [13]. Further investigation revealed three forms of estrogen: estrone, 
estriol, and estradiol, with estradiol being the primary form in premenopausal women 
[14]. A receptor for estradiol (ERa) was first reported in 1962 [15], with discovery of a 
second subtype, ER~, following in 1996 [16]. Estradiol binding to ERa results in a 
conformational change that activates the receptor, leading to its dimerization. Upon 
formation of a dimer, ERa translocates to the nucleus wherein it binds to estrogen 
response elements (EREs) in target gene promoters (Figure 1) [17,18]. ERa can also 
bind to DNA through a tethering mechanism, wherein a transcription factor such as AP-l, 
e.g., c-JunJFos, binds to specific target sequences and ERa then binds through protein-
protein interaction with AP-l [19,20]. Such a tethering mechanism can also occur 
between ERa and Spl [21,22]. Binding of ERa and associated coactivators, e.g., 
members of the SRC family or CBP/p300, leads to recruitment of RNA polymerase II for 
transcription initiation [21,23]. Work by Carroll and Brown using chromatin 
immunoprecipitation (ChIP)-sequencing (ChIP-seq) technology has identified a large set 
of estrogen-responsive genes, and expanded understanding of ERE location to include 
sequences present in far upstream enhancer regions which exert their influence on target 
gene transcription through complex chromatin looping [24,25]. Many identified ERa-
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responslve genes have roles involved in cell proliferation and survival, cell cycle 
progression, growth factor signaling, and hormone synthesis [26]. ER~ functions in 
much the same way to bind to target gene DNA and promote gene transcription. ERa 
and ER~ share many EREs in common, though ERa takes preference in binding if both 
receptors are activated by ligand [27,28] . ERa and ER~ are both activated by estradiol 
binding; however, there have been receptor-selective endogenous ligands, e.g, 5a-
androstane-3p,17p-diol (3 ~-Adiol), and synthetic ligands, e.g., 2,3-bis( 4-
hydroxyphenyl)propionitrile (DPN) for ER~ identified [29,30] . ERa and ER~ may also 
recruit different coactivators, or corepressors instead of coactivators, resulting in 
alterations in their effects on downstream gene expression [29,31]. Rather than the 
proliferative activity of ERa, ER~ has been reported to playa growth inhibitory role in 
many cell types [29,32]. 
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Peripheral tissue/breast stromal cells 
[Testosterone 1 [Androstenedione 1 
CYP19A1 ~ Y CYP19A1 
[ 1 
3/3-HSD [ 1 Estradiol _ • Estrone 
Figure 1. Model of estrogen action in the breast and inhibition by aromatase 
inhibitors and antiestrogens. 
In breast cells, estradiol binds ERa leading to its dimerization and subsequent DNA 
binding in the cell nucleus to regulate target gene expression [17,21]. The antiestrogens 
tarnoxifen and fulvestrant inhibit estradiol binding to ERa. Binding of the selective 
estrogen receptor modulator (SERM) tamoxifen to ERa leads to inhibition of coactivator 
recruitment and target gene expression [33]. Binding of the selective estrogen receptor 
downregulator (SERD) fulvestrant results in altered ligand binding domain structure, 
decreased ERa dimerization, and increased proteasomal degradation [34]. Aromatase 
inhibitors (AI) inhibit estrogen action in the breast by decreasing the conversion of the 
androgens testosterone and androstenedione to estrogens in peripheral tissues and breast 
stromal cells by inhibiting the enzyme activity of aromatase (CYP179A1) [35]. Estradiol 
has higher affinity for ERa than estrone [16] and these two estrogens are interconverted 
by 3P-hydroxysteroid dehydrogenase (3P-HSD) [36]. Androstenedione and testosterone 
can also be interconverted by 3P-HSD (not pictured) [36]. 
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BREAST CANCER TREATMENT 
Since the early 1930s when estrogen was first shown to promote breast cancer 
formation in mice [37], targeting estrogen signaling has been of interest in the treatment 
and prevention of breast cancer. In 1971, Jensen demonstrated that breast cancers with 
higher ER content exhibited a greater response to endocrine ablation than ER - cancers 
[38]. Studies such as these paved the way to the use of modem antiestrogen therapies to 
target the proliferative action of estrogen in breast cancer. Selective estrogen receptor 
modulators (SERMs) such as tamoxifen (TAM) and raloxifene (RAL) exert 
antiproliferative effects on breast cancer by competing with estrogens for binding to 
ERa (Figure 1). First developed as the contraceptive ICI 46,474 [39,40], tamoxifen acts 
as a cell type-specific agonist/antagonist of the estrogen receptor (agonist in utems and 
antagonist in breast) [33]. Binding of 4-hydroxytamoxifen, the active metabolite of 
tamoxifen, to the ligand binding domain (LBD) of ERa results in a repositioning of ERa 
helix 12 to cover the hydrophobic coactivator binding groove, preventing binding with 
coactivators [41] and resulting in an antagonist function in the breast. In other tissues, 
the increased expression of coactivators such as SRC-1 [42] or the presence of other 
tissue-specific pathways, as well as promoter-specific functions, allows tamoxifen to 
function as an agonist [43,44]. Treatment with tamoxifen leads to inhibition of cell cycle 
progression and induction of apoptosis in breast cancer cells [45,46] . The agonist activity 
of tamoxifen in the utems leads to an increased risk of endometrial cancer [47]. 
Tamoxifen has greatly increased the survival rate of breast cancer patients since its initial 
6 
FDA approval in 1977 for the treatment of metastatic breast cancer, resulting in a 32% 
reduction in annual death rate [48-50]. 
Another method of targeting the estrogen receptor is through Selective Estrogen 
Receptor Downregulators (SERD) such as the pure antiestrogen fulvestrant (ICI 
182,780), which is a steroidal 7a-alkylsulphinyl analogue of estradiol (Figure 1) [34]. 
Binding of fulvestrant to ERa results in increased ERa turnover by the 26S proteasome 
[51]. Reducing the level of ERa blocks estrogen action on target genes in breast cancer 
[34]. 
Other treatment options for breast cancer patients with ERa+ tumors include the 
use of aromatase inhibitors (AIs) [35], first proposed in 1973 [52]. In postmenopausal 
women, the ovaries no longer produce estrogens and progestins. Instead, estrogens are 
produced via the conversion of the androgens androstenedione and testosterone present 
in circulation from the adrenals by aromatase located in peripheral tissues, including 
stromal cells in breast tissue, to estrogens: estrone and estradiol, respectively by the 
enzyme aromatase (CYPI9Al) (Figure 1) [36,53,54]. Aromatase inhibitors such as 
exemestane, letrozole, and anastrozole work by inhibiting CYP19Al to stop the 
production of estrogens. In a five year study of 8,010 women, treatment with letrozole 
resulted in improved disease-free survival, overall survival, and time to distant recurrence 
for postmenopausal women, as compared to treatment with tamoxifen or a sequence of 
tamoxifen and letrozole [55] , highlighting the clinical efficacy of aromatase inhibitors as 
a treatment of choice in postmenopausal women. 
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MECHANISMS OF ENDOCRINE RESISTANCE 
Despite the initial efficacy of antiestrogen treatment, approximately 40% of 
patients relapse and die from metastatic disease because the cancer cells become 
endocrine-resistant [56]. This sequela is called acquired endocrine resistance smce 
patients first respond and then relapse. Five years of tamoxifen therapy results in a 
33.2% probability of recurrence at 15 years [49]. Many potential causes of endocrine 
resistance have been identified. Altered expression of ERa itself was identified to 
account for only 15-20% of acquired endocrine resistance [57], demonstrating that 
mechanisms other than direct loss of the antiestrogen target contribute to endocrine-
resistant phenotypes. A variant form of ERa, ERa36, has also been implicated in 
tamoxifen resistance, as ERa+ women receiving tamoxifen treatment who also had 
increased expression of ERa36 had shorter disease-free survival [58]. 
Altered coregulator expression 
A proper coactivator/corepressor ratio is necessary for basal estrogen-regulated 
gene expression. Increased coactivator or reduced corepressor expression or altered 
function has been implicated in endocrine resistance. Overexpression of coactivator 
SRC-3 has been identified in breast cancer and is correlated with reduced responsiveness 
to tamoxifen therapy [59,60]. In endocrine-resistant LY2 breast cancer cells, treatment 
with tamoxifen increased nuclear co localization of both SRC-l and SRC-3 coactivators 
with ERa, indicating tamoxifen instead acts as an ERa agonist rather than antagonist in 
these cells [61]. Further, tamoxifen treatment itself can increase the expression of SRC-l 
and SRC-3, promoting increased endocrine resistance [62]. The corepressor NCoR is 
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downregulated in a mouse model of progression to tamoxifen resistance [63]. Reduced 
NCoR expression was also found to be associated with shorter relapse-free survival of 
patients treated with tamoxifen [64]. In contrast, no correlation between the 
NCoR2/SMRT corepressor and recurrence was found through immunohistochemical 
(rnC) staining of breast tumors from tamoxifen-treated patients [65]. SMRT expression 
was instead correlated with shortened time to recurrence in untreated patients, suggesting 
a different role for this corepressor, such as in inhibition of the activity of transcription 
factors other than ERa [65]. 
Increased kinase signaling 
Nongenomic ER signaling can occur via plasma membrane (PM)-associated 
forms of ER which, when activated by ligand, stimulate rapid cellular responses through 
subsequent effects on downstream kinase activation [66-70]. ERa localization to the PM 
may be mediated through palmitoylation at cysteine 447 leading to interaction with 
caveolin-1 at lipid rafts (caveolae) in a ligand-independent manner [71,72]. Increased 
localization of ERa and a shorter splice variant ERa46 in lipid rafts occurs with HER2 
overexpression, and ERa colocalizes with HER2 in MCF-7 cells [73] . In addition to 
HER2, PM-associated ERa interacts with other growth factor receptors/receptor tyrosine 
kinases (RTKs) such as EGFR and IGFR [74,75]. Elevated EGFR and HER2 expression 
has been reported in tamoxifen-resistant breast cancer cell lines, leading to downstream 
activation of the ERK pathway [76]. Increased expression of the coactivator SRC-3 and 
HER2 enabled tamoxifen to switch to an agonistic effect in breast cancer cells, recruiting 
ERa coactivators and stimulating cell proliferation [77]. Activation of EGFR and HER2 
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signaling can also promote cell proliferation independent of the involvement of ER, 
creating a mechanism for cells to bypass the normal inhibitory effects of tamoxifen and 
other antiestrogens [78]. 
Kinases other than RTKs also have roles in progression to tamoxifen resistance. 
Protein kinase C (PKC) activation is known to increase cell proliferation [79]. Elevated 
PKCa expression was detected in breast cancer cell lines that have undergone 
progression to tamoxifen or fulvestrant resistance, and treatment with a PKC inhibitor 
reduced cell proliferation [80]. Knockdown of PKCa expression with shRNA was able 
to restore cell sensitivity to tamoxifen but not fulvestrant, suggesting the involvement of 
other pathways [80]. Ligand-activated ER can interact with PI3K to activate Akt and 
lead to subsequent signaling [81]. Reciprocally, Akt can phosphorylate ERa at serine 
167 to lead to ERa activation independent of ligand binding [82]. Tamoxifen can also 
activate Akt through phosphorylation at Serine 473 in ER+ breast cancer, which may play 
a further role in the contribution of Akt to tamoxifen resistance [83]. Inhibition of Akt 
with a PI3K inhibitor increased apoptosis in response to tamoxifen treatment [83]. 
Altered transcription factor expression/signaling 
The nuclear receptor superfamily includes ligand/steroid activated receptors, such 
as ER, that act as transcription factors to modulate target gene expression. Alteration of 
nuclear receptor signaling has been implicated in development of many types of cancer, 
including breast cancer [84] . Muscat et al. recently demonstrated expression of nuclear 
receptors COUP-TFII (gene name NR2F2) , thyroid hormone receptor ~ (TRf3) , 
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peroxisome proliferator-activated receptor y (PPARr) , and mineralocorticoid receptor 
(MR) to be predictive of metastasis-free survival in tamoxifen-treated patients [85] . 
Activation of the inflammatory NFKB pathway leads to increased expression of 
genes involved in cellular processes such as proliferation, apoptosis resistance, and other 
oncogenic functions [86]. Several groups have reported an association between increased 
NFKB pathway activation and tamoxifen resistance [87-92]. Elevated expression of one 
or more of the five subunits that comprise the NFKB transcription factor homodimer or 
heterodimer has also been reported, including upregulation of RelAlp65 in tamoxifen-
resistant breast cancer cell lines LCC9 and MCF-7IRR [87,88] and increased RelAlp65 
and NFKBlIp50 in a estrogen-independent breast cancer cell line LCCI [93]. 
Increased AP-l DNA binding was observed in a fulvestrant-resistant breast cancer 
cell line [94] as well as in a set of ERa+ tamoxifen-resistant human breast tumor samples 
[20], suggesting AP-l may provide an alternative pathway for transcription in the 
presence of antiestrogens. Increased activity of the C-Jlill NH2-terminal kinase (JNK), 
which phosphorylates and activates AP-l , was also identified in tamoxifen-resistant 
human breast tumors [20]. In addition, overexpression of C-Jlill, a member of the AP-l 
heterodimer, rendered MCF-7 cells unresponsive to endocrine therapy [95]. 
Dysregulated microRNA expression 
MicroRNAs (miRNAs) are short, noncoding RNAs of 19-25 nucleotides in length 
that downregulate gene expression post-transcriptionally via binding to the 3'UTR of 
target mRNAs in a sequence-dependent marmer leading to degradation or inhibition of 
translation. Altered expression of miRNAs in cancer has been widely reported, with 
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downstream targets in oncogemc systems such as apoptosis, proliferation, cell 
differentiation, angiogenesis, invasion, metastasis, and DNA repair [96]. Several 
miRNAs have been identified as targeting the expression of ERa, including miR-206 
[97] and miR-2211222 [98]. MiR-2211222 was significantly upregulated in tamoxifen-
resistant breast cancer cell lines and in HER2/neu+ human breast tumor samples [99]. 
Overexpression of miR-2211222 decreased the sensitivity of cells to treatment with 
tamoxifen [98]. Besides targeting ERa, miR-2211222 also targets the cell cycle inhibitor 
p27 Kipi [99]. A reduction in p27Kipi also resulted in decreased growth inhibition by 
tamoxifen treatment in breast cancer cells [99] . 
In addition to these studies, micro array analysis identified twelve miRNAs that 
were differentially expressed between MCF-7 tamoxifen-sensitive and LY2 tamoxifen-
resistant breast cancer cells [100]. Identified targets of these miRNAs had known roles in 
apoptosis (PDCD4 and BCL2), estradiol metabolism (CfPIBJ), epithelial to 
mesenchymal transition (ZEBl), and growth factor signaling (ERBB3). ERa itself was 
also identified as a target in this screen [100]. 
Altered DNA methylation 
Changes in gene promoter methylation can also occur upon progressIOn to 
antiestrogen resistance, either through activation of the expression of genes which 
promote proliferation through promoter hypo methylation (more common) or via 
downregulation of tumor suppressive genes through hypermethylation (less common) 
[101]. In one study, tamoxifen-resistant cell proliferation remained ERa-driven, while 
fulvestrant-resistant cell proliferation was driven by mechanisms other than ERa [101]. 
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Many more changes in promoter methylation were found in the fulvestrant resistant cells, 
where altered methylation was identified for 72 genes compared to only 10 genes in 
tamoxifen-resistant cells [101]. 
CONCLUSIONS 
Most breast tumors are initially driven by estrogens through activation of ERa. 
Targeting ERa by SERMs, e.g., tamoxifen, and SERDs, i.e., fulvestrant, and Als, e.g., 
letrozole, have been successful in increasing the overall survival of breast cancer patients 
in the last 25-30 yrs [33,48,102]. Unfortlmateiy, -40% of patients relapse on endocrine 
therapies [56] and understanding the mechanism by which tumors escape inhibition by 
Als, SERMs, and SERDs and re-establishing endocrine-sensitivity is key to enhancing 
overall survival. Although many mechanisms have been identified as contributing to the 
endocrine-resistant phenotype, the field is currently lacking clinically relevant biomarkers 
and functional drug targets. More work is necessary to fully elucidate the complexity of 
interactions between the current observations and translate these findings into a unified 
model of the endocrine-resistance. 
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CHAPTER II - MULTIPLE ROLES OF COUP-TFII IN CANCER INITIATION 
AND PROGRESSION 
The text of this chapter was published in Journal of Molecular Endocrinology 49(3): 
R135-48,2012. doi:1O.1530/JME-12-0144 
INTRODUCTION 
Steroid hormones and nuclear receptor ligands play critical roles in cancer 
initiation and progression and their antagonists have proven efficacy in the treatment and 
prevention of cancers. This is most notable in breast and prostate cancers and the use of 
all-trans retinoic acid for acute promyelocytic leukemia [103,104]. Steroid/nuclear 
receptors act as ligand-activated transcription factors to either positively or negatively 
regulate gene expression [84,105] . Activation of nuclear receptors occurs through 
binding a variety of ligands including hormones and vitamins/retinoids. Nuclear 
receptors (NR) have physiological roles to modulate gene expression during development 
and growth. As alteration of basal gene expression leads to many pathogenic outcomes -
including cancer, maintenance of normal gene expression by nuclear receptors is vital. 
One such critical nuclear receptor is chicken ovalbumin upstream promoter transcription 
factor II (COUP-TFII). From the time of the identification of the COUP-TF family in 
1986 [106], the many functions of COUP-TFs have continued to be explored. The role of 
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COUP-TFII in cancer is widely debated with evidence linking COUP-TFII to both tumor 
suppressive and oncogenic functions. This review will explore both the regulation and 
function of COUP-TFII and its connections to cancer. 
COUP-TFI AND COUP-TFII 
The COUP-TF family consists of two highly homologous subtypes, COUP-TFI 
and COUP-TFII, located on human chromosomes 5 and 15, respectively (Figure 2). 
COUP-TFs have been previously reviewed [107,108], but not in the specific context of 
separating COUP-TFI and COUP-TFII in cancer. COUP-TFs are ancient NRs and are 
located close to retinoid X receptors (RXRs) in the evolutionary tree [109,110]. As 
evolutionarily conserved transcription factors, COUP-TFs have major roles in 
development. The importance of COUP-TFII expression is evidenced by studies III 
knockout mice [111]. Homozygous mutation of COUP-TFII leads to embryonic lethality 
due to impaired angiogenesis and heart defects, resulting in hemorrhage and edema. 
These effects may in part be explained by the reduction in angiopoietin-1 expression in 
COUP-TFII-null mice [111]. Other important embryonic roles for COUP-TFII include 
regulation of limb growth and muscle development [112] . COUP-TFII-null mice display 
a reduction in expression of Lbxl, a protein required for proper muscle precursor cell 
migration, and in myogenin, which is necessary for muscle cell differentiation [112,113]. 
Based on the high sequence identity in their DNA binding domains DBDs (Figure 
2), we anticipate that COUP-TFI and COUP-TFII regulate the same genes. However, 
this has not been empirically tested and it is worth noting that the N-terminus is divergent 
(Figure 2) and immunoprecipitation studies indicate differences in proteins interacting 














Figure 2. Comparison of COUP-TFI and COUP-TFll protein homology. 
COUP-TFI (NP _005645.1) and COUP-TFII (NP _066285. 1) amino acid sequences were 
obtained from the National Center for Biotechnology Information. The COUP-TF DNA 
binding domains (DBD) and ligand binding domains (LBD) share 99% and 97% amino 
acid homology, respectively. Positions noted as important in coactivator recognition are 
shown in orange. 
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systematically studied in cells in which both are expressed. COUP-TFI and COUP-TFII 
may have divergent functions in certain contexts as well. Differences in COUP-TFI and 
COUP-TFII function in breast cancer endocrine sensitivity, for example, have also been 
identified [116]. This review will focus specifically on COUP-TFII. 
COUP-TFII REGULATION OF GENE EXPRESSION 
Mechanisms of regulation 
COUP-TFII can activate or repress gene expression in both a tissue-specific and 
gene-specific manner through mechanisms involving direct binding to DNA response 
elements or binding to other transcription factors. Through binding to 5' -AOGTCA-3' 
direct repeats (DR) with variable spacing [117], COUP-TFII modulates the expression of 
target genes. Specific genes upon which COUP-TFII activates transcription include 
retinoic acid receptor ~2 (RAR~2, RARB2) [115,118], phosphoenolpyruvate 
carboxykinase (PEPCK, PCKl) [119], NGFI-A [120,121], and cholesterol 7a-
hydroxylase (CYP7Al) [122]. COUP-TFII action may be potentiated by interaction with 
coactivators such as steroid receptor coactivator family members SRC-1/NCOAl, SRC-
2/NCOA2, and SRC-3INCOA3 [120,121], as well as PGCla [120], p300lCBP [121], 
orphan receptor coactivator (ORCA) [123], and nucleolin [115] . DNA binding of COUP-
TFII can promote the binding of a second transcription factor, further activating gene 
transcription. This occurs for both the PEPCK and CYP7 Al genes, where COUP-TFII 
binding to the promoter recmits binding of glucocorticoid receptor (OR) to enhance gene 
expression [119,124]. COUP-TFII can also bind to Spl sites to cooperatively activate 
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gene expression, as was reported for regulation of Otx2 expression during morphogenesis 
in the mouse eye [125]. 
Alternatively, binding of COUP-TFII to DRs may result in repression of gene 
expression. In the mechanism of "active repression," COUP-TFII binding results in 
recruitment of corepressors, i.e., nuclear corepressor (NCoR) [126] and silencing 
mediator of retinoid and thyroid receptors (SMRT) [127,128], resulting in repressed 
chromatin structure and a corresponding blockade of target gene transcriptional 
activation. COUP-TFII interaction with SMRT represses PPARyl and PPARY2 
expression to suppress adipogenesis [128]. Repression of the human oxytocin promoter 
by COUP-TFII binding has also been reported [129]. COUP-TFII represses Pax2 
expression in the retina via binding to a DRI site (TGTTCACAGTCCA) [125]. 
Through an alternative mechanism of transrepression, COUP-TFII can interact 
with other nuclear receptors and transcription factors to inhibit their normal 
transcriptional activity. Examples of this include inhibition of ER- and GR-induced gene 
expression in a gene-specific manner [119,130]. COUP-TFII can also repress AP-l 
signaling through interaction with c-Jun [131]. Interaction of COUP-TFII with Runx2 
inhibits osteoblast differentiation via blocking Runx2 binding to the osteocalcin promoter 
[132]. Other mechanisms of repression involve the modulation of ER, RXR, PP AR, and 
VDR activity by competing for DNA response element-binding or heterodimerization 
with the class II heterodimeric partner RXR [133]. 
Ingenuity Pathway Analysis 
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As summarized here, COUP-TFII regulates the expression of diverse gene targets. 
Table 1 contains a list of known COUP-TFII targets as identified using Ingenuity 
Pathway Analysis (IPA; Ingenuity Systems, www.ingenuity.com). These targets are also 
displayed in Figure 3. COUP-TFII has varying effects on expression of other nuclear 
receptors and transcription factors. COUP-TFII increased the expression of HNF-la 
[134], HNF-l~ [135], HNF-4a [136], and RAR~ [115,118,137], while it decreased the 
expression of Oct4 [138,139], Daxl [140], and PPARa [141]. As previously described, 
COUP-TFII has well known functions in repressing the transcriptional activity of other 
nuclear receptors and transcription factors. Although COUP-TFII increases HNF-4 
expression, other reports highlight the repression of HNF-4 function by COUP-TFII. 
Specifically, COUP-TFII decreases transcriptional activation of ALDH2 [142] and retinol 
binding protein 2 (RBP2) [143] by HNF-4. The HNF-4 activation of hepatic lipase is 
suppressed by COUP-TFII [144], while lipoprotein lipase expression is induced by 
COUP-TFII synergistically with PPARr [145] ; part of the many of reported functions of 
COUP-TFII in the cholesterol processing pathway. A similar response occurs for 
apolipoproteins A-I, A-IV, and C-III, where COUP-TFII represses the RXRa-mediated 
expression of APOA-I [135,146,147] and HNF4-mediated expression of APOA-IV 
[148,149] and APOC-III [134,135,150,151]. HNF-4 and COUP-TFII binding to the sex 
hormone binding globulin (Shbg) promoter was reported in murine Sertoli cells [152]. 
SHBG expression is increased by HNF-4 and suppressed by COUP-TF in HepG2 
hepatoblastoma cells [153]. Decreased SHBG expression is indicative of metabolic 
syndrome and may result in increased plasma androgen and estrogen levels, though the 
precise connection of COUP-TFII to these phenotypes has not been investigated [154]. 
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Although COUP-TFII is classically known for.its role in transrepression, COUP-
TFII may also enhance the effect of a second nuclear receptor. Induction of cytochrome 
P450 family members cholesterol 7a-hydroxylase CYP7 Al [122] and aldosterone 
synthase CYPllB2 [155,156] by COUP-TFII was reported, with COUP-TFII and HNF-4 
acting to synergistically activate CYP7Al [122]. CYP7Al catalyzes the first step in the 
conversion of cholesterol to bile acid [122], while CYPIIB2 catalyzes the final steps of 
aldosterone synthesis [155], implying that COUP-TFII transcriptional activation would 
increase the production of bile acid and aldosterone. 
As shown in Table 1 and Figure 3, COUP-TFII opposes PPARylRXR activation 
of PEPCK transcription in predadipocytes/fibroblasts, a result that was proposed to 
suppress adipogenesis [157]. COUP-TF also inhibited 9-cis retinoic acidlRXR-induced 
activation of the lactotransferrin promoter in transiently transfected ZR-75-1 and Hs578T 
breast cancer cells apparently by competing for DNA binding to a composite RAREIERE 
in the gene promoter [158]. Concurrent binding of COUP-TFII and NF-Y to the 
hemoglobin epsilon promoter leads to a repression of gene expression [159]. In addition 
to the targets identified by lP A, COUP-TF was reported to playa dual regulatory role in 
the transcriptional regulation of the mitochondrial HMG-CoA synthase gene: alone 
COUP-TFI stimulated reporter gene activity from the HMG-CoA synthase promoter in 
transiently transfected HepG2 human hepatoma and rat Leydig tumor R2C cells, but it 
inhibited PP ARa-stimulated transcriptional activity by competing for the same DNA 
binding site [160]. 
Some of the lPA-identified COUP-TFII target gene relationships and mechanisms 





Figure 3. COUP-TFll (NR2F2) target genes. 
1 
COUP-TFII has been reported to modulate the expression ofa variety of target genes 
both positively and negatively. A list of COUP-TFII target genes and corresponding 
network pathway were generated using Ingenuity Pathway Analysis (IP A; Ingenuity 
Systems, www.ingenuity.com). 
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Table 1. List of COUP-TFII-regulated genes identified by Ingenuity Pathway 
Analysis 
Gene Regulation 
(protein) Name Location Family by COUP- Reference 
TFII 
ALDH2 
Aldehyde dehydrogenase 2 family 
Cytoplasm Enzyme Decrease [142] (mitochondrial) 
ANGPT1 Angiopoietin 1 
Extracellular 
Growth factor Increase [111] 
Space 
APOA1 Apolipoprotein A-I 
Extracellular 
Transporter Decrease [135,146,147] 
Space 
APOM Apolipoprotein A-IV 
Extracellular 
Transporter Decrease [148,149] Space 





Aldosterone synthase, cytochrome 
CYP11B2 P450, family 11 , subfamily B, Cytoplasm Enzyme Increase [155,156] 
polvpeptide 2 
Cholesterol 7 alpha-hydroxylase, 
CYP7A1 cytochrome P450, family 7, Cytoplasm Enzyme Increase [122] 
subfamily A, polypeptide 1 
GATA6 GATA binding protein 6 Nucleus 
Transcription Decrease 
[161] reQulator sUQQested 
HBE1 Hemoglobin, epsilon 1 Cytoplasm Transporter Decrease [159,162] 
HNF1A HNF1 homeobox A Nucleus 
Transcription 
Increase [134,161J regulator 




HNF4A Hepatocyte nuclear factor 4, alpha Nucleus 
Transcription 
Increase [136] regulator 
VEGFR-2; kinase insert domain 
Plasma 
KDR receptor (a type III receptor 
Membrane Kinase Decrease [163] 
tyrosine kinase) 
L1PC Lipase, hepatic 
Extracellular 
Enzyme Decrease [144J Space 
LPL Lipoprotein lipase Cytoplasm Enzyme Increase [145J 
LTF Lactotransferrin 
Extracellular 
Peptidase Decrease [158J Space 
NPPA Natriuretic peptide A 
Extracellular 
Other Increase [164] Space 
NROB1 Dax1 , nuclear receptor subfamily Nucleus Ligand-dependent Decrease [140] 0, group B, member 1 nuclear receptor 
NR1H4 
FXR, nuclear receptor subfamily 1, 
Nucleus 
Ligand-dependent 
Unknown [161J group H, member 4 nuclear receptor 
NR112 PXR, nuclear receptor subfamily 1, Nucleus 
Ligand-dependent 
Unknown [161J Qroup I, member 2 nuclear receptor 
NR5A2 LRH-1, nuclear receptor subfamily Nucleus 
Ligand-dependent 
Unknown [161J 5, group A, member 2 nuclear receptor 
NRP1 Neuropilin 1 
Plasma Transmembrane 
Decrease [163J Membrane receptor 
PCK1 
Phosphoenolpyruvate 
Cytoplasm Kinase Decrease [157] carboxykinase 1 (soluble) 
POU5F1 Oct 4; POU class 5 homeobox 1 Nucleus 
Transcription 
Decrease [138,139J reQulator 
PPARA 
Peroxisome proliferator-activated 
Nucleus Ligand-dependent Decrease [141] receptor alpha nuclear receptor 
RARB Retinoic acid receptor, beta Nucleus 
Ligand-dependent 
Increase [115,118,137, nuclear receptor 1431 
RBP2 Retinol binding protein 2, cellular Cytoplasm Transporter Decrease [143J 
SHBG Sex hormone-binding globulin 
Extracellular 
Other Decrease [152,153J Space 
Solute carrier family 9, subfamily A 
Plasma 
SLC9A1 (NHE1 , cation proton antiporter 1), 
Membrane Ion channel Increase [165J 
member 1 
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hepatic development, COUP-TFII occupancy of GATA-6, FXR, PXR, and LRH-J 
promoters, as determined by chromatin immunoprecipitation (ChIP) assay, was reported 
during the postnatal period [161]. While an inhibitory relationship was suggested for the 
effect of COUP-TFII on GATA-6, the effect on FXR, PXR, and LRH-J expression is not 
yet known [161]. Several other target genes have been identified that highlight the 
critical function of COUP-TFII in the vascular system. These include an increase in 
angiopoietin 1 [111] and natriuretic peptide A [164] by COUP-TFII, and a decrease in 
VEGFR-2 and neuropil in 1 [163]. COUP-TFII enhances expression of the NHE1 solute 
exchanger [165,166]. 
In summary, as indicated by the IPA (Figure 3) and consistent with previous 
reports, COUP-TFII plays a role in many downstream pathways and may either activate 
or suppress gene expression. 
Role in the retinaic acid pathway 
COUP-TFs are classified as orphan members of the NR superfamily, because 
their endogenous ligand(s) is not known. However, Kmse et al demonstrated in silica 
binding of all-trans (atRA) and 9-cis (9cRA) retinoic acid to the crystal stmcture of the 
COUP-TFII LBD [120]. RA released the COUP-TFII LBD from the autorepressed 
conformation. While the investigators did not directly test binding of all-trans or 9-cis 
RA to COUP-TFII, they demonstrated that treatment with atRA or 9cRA increased 
COUP-TFII interaction with the coactivator SRC-3, with an ECso of 1O-30~. In 
agreement with this data, addition of 20 /-lM atRA or 9cRA led to COUP-TFII' s 
activation of a NGFI-A-luciferase reporter [120]. Although these concentrations of atRA 
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and 9cRA are greater than the physiological concentration of these retinoids, this finding 
provides novel insight into the ligand binding ability of COUP-TFIL Indeed, the function 
of this activation can be seen in the regulation of RAR~2 by COUP-TFII, as COUP-TFII 
activation of RAR~2 expression is increased with the addition of all-trans retinoic acid 
[115,118], Treatment of MCF-7 breast cancer cells with atRA also increased COUP-
TFII-binding to the RARB2 promoter in a ChIP assay [115]. Retinoic acid induces the 
expression of COUP-TFII in certain breast cancer cell lines (e.g. T47D and ZR-75) but 
not others (e.g. MCF-7 and MDA-MB-231) (Figure 4) [115,167]. This indicates a 
potential feed forward loop, as treatment with retinoic acid may increase both the 
expreSSIOn and activation of COUP-TFII, with downstream effects on retinoic acid 
receptor. 
REGULATION OF COUP-TFII EXPRESSION 
Tissue-specific regulation in humans 
COUP-TFII has a widespread tissue distribution, with detectable expression in 
every human tissue type examined [168]. The regulation of COUP-TFII expression is 
tissue and cell-type specific, and can be modulated both transcriptionally and post-
transcriptionally (Figure 4). Hyperinsulinemia is a risk for breast cancer [169,170], 
COUP-TFII expression was repressed by insulin and glucose in the liver and pancreas of 
C57BL6/J mice and in mouse primary hepatic and pancreatic cell culture [171]. In 
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Figure 4. Regulation of COUP-TFII expression. 
COUP-TFII expression has been shown to be modulated both transcriptionally and post-
transcriptionally by a variety of transcription factors, signaling pathways, and various 
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Figure 5. Insulin treatment does not affect COUP-TFII expression in human breast 
cancer cells. 
MCF-7 and T47D human breast cancer cells were grown as in described in [115] . As 
T47D growth medium contains 6 mg/ml insulin, T47D cells were either grown in normal 
medium (with insulin) or in insulin-free medium to determine if this affected outcome. 
Prior to treatment with insulin, all cells were "starved" in low glucose medium (5 mM 
glucose) for 24 h [136,171]. Cells were treated for 6 h with the indicated concentrations 
of insulin. QRT-PCR was performed to measure NR2F2 expression relative to GAPDH 
as a reference gene, as described in [115]. Insulin treatment had no statistically 
significant effect on COUP-TFII expression in these cell lines. 
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MCF-7 and T47D breast cancer cells (Figure 5). The lack of alteration in COUP-TFII 
expression with insulin in breast cancer cells highlights the importance of cell-specific 
regulation of COUP-TFII expression. There are currently no reports on the effect of 
insulin on COUP-TFII expression in other cancers. 
miRNA regulation 
MicroRNA (miRNA) expression is altered in a variety of conditions and disease 
states, including cancer, and results in important post-transcriptional regulation of crucial 
proteins [96]. While 115 miRNAs are predicted to target NR2F2 
(http://cometa.tigem.it/site/index.php), only one miRNA has been verified. rniRNA-302 
directly represses COUP-TFII expression in human embryonic stem cells [138]. 
Regulation of COUP-TFII expression by miRNA has not yet been reported in cancer 
cells. 
DNA methylation 
Methylation at CpG islands can result in suppression of gene transcription, and is 
known to be a hallmark of cancer progression. DNA methylation may also occur at 
intragenic and intergenic sites, as well as at the promoter [172,173]. Specifically, COUP-
TFII has been found to be methylated in many cancers, including mantle cell lymphoma, 
acute myeloid leukemia, salivary gland adenoid cystic carcinoma, pancreatic 
adenocarcinoma, colon cancer, breast cancer ductal carcinoma in situ, as well as a 
tamoxifen-resistant breast cancer cell line [101,174-179]. NR2F2 gene hypermethylation 
was associated with a concordant reduction in rnRNA expression in mantle cell 
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lymphoma, pancreatic cancer, and tamoxifen-resistant breast cancer cells [101,174,177]. 
Whether this indicates a general trend of reduced COUP-TFII expression due to 
epigenetic modification across cancer types remains to be seen. Contrary to these 
reports, high levels of COUP-TFII mRNA expression were found in all cell lines in the 
NCI60 panel of human cancer cell lines [180]. 
Regulation by other transcription factors 
COUP-TFII and Ets-l have overlapping expression patterns in mesenchymal cells 
of the mouse gut, spleen, lungs, and other tissues [181]. Members of the ETS family 
(Ets-l, Ets-2, ETV, PEA3, Spi-l, and ERM) increased murine COUP-TFII-promoter 
activity in HeLa cells. Steroid receptor coactivators SRC-IINCOAl, TIF2/SRC-
2INCOA2, and RAC3/SRC-3INCOA3 enhanced the activation of the COUP-TFII 
promoter [181]. In agreement with this data, SRC-3 and RARa increased COUP-TFII-
promoter activity in HepG2 human hepatocellular carcinoma cells with atRA treatment. 
Reciprocally, siRNA knockdown of SRC-3 repressed COUP-TFII expression [182]. We 
observed that the protein expression (by immunohistochemical staining) of AIB lISRC-
3/NCOA3, PEA3, and SRC-IINCOAI were correlated with COUP-TFII in breast cancer 
patient samples [115]. 
Regulation by altered kinase activity and other signaling pathways 
Several factors were reported to alter COUP-TFII expression in pathogenic states. 
More et al reported that expression of COUP-TFII, but not COUP-TFI, is stimulated by 
activation of the MAP kinase (MAPK) pathway. Breast cancer cell lines with increased 
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MAPK activity, i.e., SKBR3, had a concomitant increase in COUP-TFII expression 
[183]. In contrast to the idea that MAPK activation increases COUP-TFII expression, 
MAPK has also been shown to phosphorylate and inactivate PP2A (protein phosphatase 
2A), leading to a suppression of COUP-TFII expression in human peripheral blood 
CD34+ cells [184]. Inactivation of PP2A also inhibits sonic hedgehog-induced COUP-
TFII expression in P19 cells [185] . PP2A is inhibited by the FOXO transcription factors, 
including FOXOI [186]. COUP-TFII expression is induced by FOXOI in pancreatic 
beta cells and hepatocytes [171], highlighting the highly cell type-specific nature of these 
pathways. MAPK activity may lead to increased COUP-TFII expression in certain 
conditions, while it may alternatively repress COUP-TFII in others. Taken together, 
these data suggest a possible feedback loop in certain cell types (Figure 4). 
In addition to MAPK activation, Notch signaling is also dysregulated in many 
types of cancer. Increased Notch signaling has been implicated in carcinogenesis and 
metastasis and is also involved in regulation of endothelial cell proliferation and 
angiogenesis [187,188]. In breast cancer, Notch and its ligand Jaggedl upregulate the 
expression of Slug, a transcriptional repressor of E-cadherin important in metastatic 
progression [189]. Notch signaling has also been implicated in the amplification of 
HER2 and survival of tumor initiating cells [190] and cancer stem cells [188,191,192]. 
Activation of the Notch pathway confers cancer-like properties and apoptosis-resistance 
to normal breast epithelial cells [193]. Regulation of COUP-TFII by Notch signaling has 
been reported in endothelial cells of both arterial and venous origin and in mouse studies 
[163,194,195]. Notch can suppress COUP-TFII and Pro spero-related homeobox domain 
1 (Proxl), leading to an arterial rather than lymphatic phenotype in endothelial cells 
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[163,194,196]. COUP-TFII, in turn, can also suppress Notch signaling to result in vein 
rather than artery formation [195]. Transforming growth factor-~l (TGF~l) suppresses 
COUP-TFII expression in keratinocytes and fibroblasts leading to induction of collagen 
type VII (COL7Al) expression [197] and in vascular progenitor cells to negatively 
regulate lymphvasculogenesis [198]. Whether COUP-TFII is regulated via Notch and 
TGF~l signaling has not yet been explored in cancer. 
Amplification of Wnt/~-catenin signaling has been widely reported in cancer 
[199]. In normal tissues, ~-catenin signaling is controlled through signals leading to its 
phosphorylation by a multiprotein destruction complex and subsequent degradation. In 
breast and other cancers, increased expression of Wnt ligands leads to maintenance of ~­
catenin activation by preventing its degradation [199]. ~-catenin signaling has many 
outcomes, such as normal mammary morphogenesis and ductal maturation; however, 
sustained activation, through a variety of mechanisms, leads to carcinogenesis [199]. 
ChIP assays demonstrated that ~-cateninJTCF7L2 (T-cell factor 7-like 2 or transcription 
factor 7-like 2) bind the promoter of COUP-TFII to activate expression, resulting in 
suppression of adipocyte differentiation [128]. COUP-TFII is expressed in mouse liver 
and pancreatic ~-cells and plays roles in the maintenance of glucose homeostasis and 
insulin sensitivity [171,200]. Boutant et at also reported that ~-cateninlTCF7L2 induces 
COUP-TFII expression in the pancreas, and that COUP-TFII expression was necessary 
for normal ~-cell function and glucose tolerance in mice [201]. The influence of ~­
catenin signaling on COUP-TFII expression in cancer has yet to be examined. 
30 
ROLE OF COUP-TFII IN CANCER 
Angiogenesis 
Many studies of COUP-TFII involve its regulation of the angiogenesis pathway. 
Under normal conditions, angiogenesis is not active after the time of vasculature 
development during embryogenesis. However, upon progression of a tumor's growth, 
activation of angiogenesis leads to the formation of new blood vessels to support the 
tumor [202]. COUP-TFII is necessary during normal development for angiogenesis and 
lymphangiogenesis, as evidenced by the impaired vessel formation and embryonic 
lethality in COUP-TFII knockout mice [111 ,203]. The expression of many pro-
angiogenic factors is modulated by COUP-TFII, including members of the vascular 
endothelial growth factor (VEGF) family and their receptors. VEGF induces 
angiogenesis and lymphangiogenesis by activating tyrosine kinase receptors and 
upregulates endothelial cell proliferation and migration [204]. In a model of pancreatic 
islet tumorigenesis, ablation of COUP-TFII increased VEGFR-l expression, impairing 
VEGFR-2 signaling and reducing angiogenesis [205]. Metastasis to regional lymph 
nodes was reduced as a result, implying that COUP-TFII may have a pro-angiogenic, 
pro-metastatic role in pancreatic cancer [205]. Similarly, ablation of COUP-TFII 
decreased tumorigenesis in BI6-FlO melanoma and Lewis lung carcinoma mouse 
xenografts, and reduced tumorigenesis and metastasis in a spontaneous mouse mammary 
tumor model. These effects were attributed to a decrease in blood vessel density in 
COUP-TFII-deficient mice [206]. 
In addition to regulating VEGFR expression, COUP-TFII can also affect 
angiogenesis .via regulation of angiopoetin-l (Ang-l ), through binding to an Spl site in 
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the promoter region. The induction of Ang-1 is partially responsible for the effects of 
COUP-TFII, as overexpression of Ang-1 allowed for recovery of angiogenesis in COUP-
TFII-deficient mice [206]. 
Lymphangiogenesis can also contribute to metastasis by allowing the spread of 
tumor cells to lymph nodes [207,208]. COUP-TFII regulates tumor lymphangiogenesis 
via inducing expression of VEGF-C and neuropilin-2, a coreceptor for VEGF-C 
[203,209]. In a murine model of pancreatic islet tumorigenesis, COUP-TFII deletion 
resulted in impaired lymphangiogenesis and reduced metastasis [205]. Concordant with a 
role for COUP-TFII in lymphangiogenesis, Kang et al reported that Notch suppresses 
COUP-TFII expression, along with Prox1, in human primary dermal lymphatic 
endothelial cells to signal for arterial rather than lymphatic differentiation [163]. 
Suppression of COUP-TFII resulted in an increase in VEGF signaling by activating 
expression of VEGFR-2, a VEGF receptor whose signaling can feedback to increase 
activation of Notch signaling [163]. 
COUP-TFII induction by 9cRA was also shown to promote network formation 
but not cell fusion in SKBR3 breast cancer cells, suggesting a role in the endothelial 
trans differentiation pathway as a necessary part of vascular formation [210]. Taken 
together, these data indicate that COUP-TFII may regulate angiogenesis and 
lymphangiogenesis, primarily through modulation of VEGF and its receptor in a cell 
context-dependent manner. 
Invasion and metastasis 
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In addition to stimulation of angiogenesis, COUP-TFII may have other distinct 
roles in regulation of tumor growth and metastasis. Transfection with COUP-TFII in 
A549, H520, and H441 lung cancer cells and MDA-MB-231 breast cancer cells was 
reported to increase migration and invasion [211]. Navab et al found that COUP-TFII 
upregulated the expression of extracellular matrix-degrading proteinases matrix 
metalloproteinase 2 (MMP2) and urokinase-type plasminogen activator (uPA) [211]. 
MMP2 and uPA are known to play critical roles in cancer, particularly in angiogenesis 
and metastasis [212]. High levels of uPA are predictive of recurrence but also of a 
favorable response to adjuvant chemotherapy in breast cancer patients [213]. 
Interestingly, it has also been reported that uPA expression is dependent on Notch 
signaling in MDA-MB-231, MDA-MB-468, and HCC1143 breast cancer cells [214]. 
COUP-TFII and MMP2 expression were also positively correlated in a breast tumor 
micro array [115], further indicating a potential relationship between COUP-TFII and 
extracellular matrix degradation. In contrast, COUP-TFII decreased cell motility when 
transfected into L Y2 tamoxifen-resistant breast cancer cells, while having no significant 
effect on invasion [116]. 
Estrogen receptor and clinical outcome 
Nagasaki et al demonstrated that COUP-TFII expression was correlated with ERa 
status and indices of poor clinical outcome (clinical stage, lymph node status, histological 
grade) in human breast tumor samples, indicating COUP-TFII may playa role in cancer 
progression [209]. We also found that COUP-TFII and ERa expression were correlated 
in a human breast tissue/tumor micro array, but instead noted an inverse relationship 
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between COUP-TFII expression and TNM (tumor, node, metastasis) classification [115]. 
Similar findings were observed at the mRNA level by examining breast tumor rnRNA 
transcriptomes in Oncomine [115]. COUP-TFII expression was significantly higher in 
ERa+ breast cancer samples and significantly lower in metastatic samples [115]. These 
findings indicate a function for COUP-TFII in inhibiting tumor progression. A positive 
correlation with ERa is consistent with a previous report that siRNA knockdown of ERa 
in MCF-7 breast cancer cells decreased COUP-TFII expression and treatment with 
estradiol increased the expression of COUP-TFII [116]. ERa is a positive prognostic 
factor in breast tumors and is the target of endocrine-targeted cancer therapeutics such as 
the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene [48]. 
COUP-TFII, but not COUP-TFI, is reduced in tamoxifen-resistant human breast cancer 
cells, and re-expression of COUP-TFII can restore tamoxifen-sensitivity [116]. As ERa 
expression is important in keeping breast cancer cells responsive to treatment, the 
correlation of COUP-TFII and ERa further demonstrates a beneficial role for COUP-
TFII, highlighting its potential importance in maintaining differentiation and endocrine 
sensitivity. 
In contrast to a role for COUP-TFII in maintaining antiestrogen sensitivity, 
Holbeck et al reported that cancer cells in the NCl60 panel expressing low levels of 
COUP-TFII showed higher sensitivity to microtubule-targeting drugs vinblastine, 
co1chicines, and taxol [180]. These data demonstrate that both cell type-specific as well 




COUP-TFII expression was reported to be high in aldosteroma, with an inverse 
correlation to adrenal steroidogenesis [215]. These data also indicated an inverse 
correlation between COUP-TFII expression and CYP17Al expression, with COUP-TFII 
inhibiting CYP17Al in aldosteroma [215]. COUP-TFII competed with SF-l for binding 
to overlapping sites within the promoters of the CYP17Al [216,217], CYPllAl, and 
STARDI genes in rat Leydig cells and to suppress testosterone production [216]. COUP-
TFI and COUP-TFII both repressed angiotensin II-stimulated STARDI (StAR) in bovine 
adrenal glomerulosa cells in primary culture [218]. COUP-TFII also competed with SF-l 
for the human aromatase P450 promoter II in primary endometriotic stromal cells and 
suppressed aromatase expression.[219]. Overexpression of SF-l in primary 
endometriotic stromal cells outcompeted the normal protective effect of COUP-TF 
(whether COUP-TFI or COUP-TFII was involved was unclear since both were equally 
expressed at the mRNA level) resulting in high local aromatase expression in 
endometriosis [219]. COUP-TFII was reported to bind the SI silencer region of the 
human aromatase gene and suppress transcription in MCF-7 cells [220]. Indeed, the 
decreases in COUP-TFI, EARy, EAR-2, Snail and Slug in breast cancer were suggested 
to increase aromatase expression [221]. Thus, the downregulation of COUP-TFII 
expression that we observed in endocrine-resistant breast cancer cells [116] would be 
expected to increase aromatase and thus increase local estrogen production. However, 
whether increased COUP-TFII suppresses local androgen or estrogen biosynthesis in 
breast tissue is unknown. Local conversion of adrenal androgens to estrogens by 
aromatase is the target of AI therapy for post-menopausal women. However, there are 
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androgen metabolites, e.g., 3~-adiol, that bypass aromatase which activate ERa and ER~ 
and may playa role in AI resistance [222,223]. Overall, the literature supports a negative 
role for COUP-TFII in regulating steroid hormone synthesis and further studies 
addressing COUP-TFII regulation of aromatase gene expression in local estrogen 
production in breast [224] and lung [225] adenocarcinomas would be of merit. 
CONCLUSIONS 
The studies reviewed here indicate that COUP-TFII is regulated and is 
functionally active to regulate target gene transcription in a cell type-dependent manner. 
There is evidence that COUP-TFII may perform both pro- and anti-tumorigenic roles. 
COUP-TFII has been repolted to increase angiogenesis and lymphangiogenesis, both 
increase and decrease tumor metastasis, lead to favorable and unfavorable therapeutic 
outcome in cancer therapy, and suppress steroidogenesis. Qin et al reported that COUP-
TFII was not expressed in tumor cells, but rather was instead found in high concentration 
in the surrounding blood vessels that support tumor growth and spread [206]. This 
indicates a crucial point of consideration about the nature of COUP-TFII in cancer 
formation and progression: the function of COUP-TFII within cancer cells versus in the 
surrounding tumor microenvironment and other cell types. Tissue type is clearly an 
important determinant in deciphering the oncogenic or tumor-suppressive nature of 
COUP-TFII. Many studies published to date involve the regulation and role of COUP-
TFII during development and in non-cancerous disease states. The full applicability of 
these studies to our knowledge of the role of COUP-TFII in carcinogenesis and cancer 
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progression remains to be seen. Future studies are necessary to elucidate the complex 
nature of this vital nuclear receptor. 
DISSERTATION SPECIFIC AIMS AND HYPOTHESES 
Despite the initial efficacy of tamoxifen and other antiestrogens, approximately 
40% of patients relapse and die from metastatic disease, in part because the cancer cells 
become endocrine-resistant [56]. Identification of proteins and pathways key in the 
progression to endocrine resistance is essential for the development of improved 
treatments for patients. Our lab has previously reported that the expression of COUP-
TFII, but not COUP-TFI, is reduced upon progression to endocrine resistance, and that 
overexpression of COUP-TFII can restore endocrine sensitivity [116]. As reviewed in 
chapter 2, many reports on the cellular roles of COUP-TFII are contradictory and fail to 
provide insight necessary to understand the mechanism of COUP-TFII action in 
endocrine-resistant breast cancer [226]. The overall goal of this study was to identify 
and evaluate the function of proteins that interact with COUP-TFII to define the role of 
COUP-TFII in breast cancer and endocrine sensitivity. COUP-TFII may be both a useful 
biomarker to predict tamoxifen-sensitivity as well as a target to restore endocrine 
sensitivity to resistant cells. The overall hypothesis was that the activity of COUP-TFII 
in maintenance of endocrine sensitivity and cell differentiation is dependent on its 
interacting proteins. 
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SPECIFIC AIM 1: Characterize the interaction of COUP-TFII and nucleolin. 
I tested the hypothesis that COUP-TFII and nucleolin interact directly in MCF-7 and 
T47D breast cancer cells. COUP-TFII and nucleolin interaction was evaluated in MCF-7 
and T47D cells through co-immunoprecipitation. In vitro binding was assessed through a 
maltose binding protein (MBP) pulldown assay. COUP-TFII and nucleolin expression 
were analyzed in human breast cancer patient samples through immunohistochemistry. 
SPECIFIC AIM 2: Determine how the interaction of COUP-TFII and nucleolin 
affects target gene expression in breast cancer cells. 
I tested the hypothesis that nucleolin functions as a coregulator for COUP-TFII in the 
expression of the COUP-TFII target gene RARB2. The ability of nucleolin to function as 
a coactivator for COUP-TFII was analyzed in MCF-7 and T47D cells. Transient 
transfection, siRNA knockdown, luciferase assays, and other assays were used to 
determine the contribution of nucleolin to RARB2 expression. 
SPECIFIC AIM 3: Determine if COUP-TFII expression modulates NFKB activity in 
endocrine-resistant breast cancer cells. 
I tested the hypothesis that COUP-TFII suppresses NFKB activity in breast cancer cells 
through a mechanism involving suppression of NFKB transcription. The effect of COUP-
TFII on NFKB activity was assayed in endocrine-sensitive MCF-7 versus endocrine-
resistant LCC9 breast cancer cells using luciferase assays and electrophoretic mobility 
shift assays (EMSA). NFKB subunit and target gene expression was examined using 
QRT-PCR and western blots. 
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SPECIFIC AIM 4: Determine the identity of proteins that interact with COUP-TFII 
in tamoxifen-treated MCF -7 human breast cancer cells. 
I tested the hypothesis that 4-0HT treatment changes the interaction of COUP-TFII with 
other nuclear proteins in MCF-7 endocrine-sensitive cells and that these proteins are 
important in mediating the ability of antiestrogens to inhibit cell proliferation. MCF-7 
breast cancer cells were transiently transfected with FLAG-tagged COUP-TFII and 
treated with ethanol (EtOH, vehicle control) or 4-0HT before immunoprecipitation was 
performed using a FLAG antibody to capture COUP-TFII and associated proteins. Mass 
spectrometry identified proteins interacting with COUP-TFII specifically when treated 
with EtOH versus 4-0HT. Further experiments including co-immunoprecipitation, 
transient transfection, western blots, and QRT -PCR were performed to analyze the role of 
the identified COUP-TFII-interacting proteins. 
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CHAPTER III - IDENTIFICATION AND CHARACTERIZATION OF 
NUCLEOLIN AS A COUP-TFII COACTIVATOR OF RETINOIC ACID 
RECEPTOR ~ TRANSCRIPTION IN BREAST CANCER CELLS 
The text of this chapter was published in PLoS QNE 7(5): e38278, 2012. 
doi: 10. 13711joumal.pone.0038278 
INTRODUCTION 
COUP-TFI (NR2Fl) and COUP-TFII (NR2F2) are 'orphan' members of the 
steroid/nuclear receptor (NR) superfamily [107]. COUP-TFs regulate gene transcription 
in a cell- and gene- specific manner. COUP-TFII differs from COUP-TFI at the N-
terminus, but is conserved within the DNA binding and ligand binding domains (DBD 
and LBD) [107]. Gene knockout mice demonstrated that COUP-TFI (Nr2fl) and COUP-
TFII (Nr2j2) have distinct roles during embryogenesis, notably in the nervous and 
cardiovascular systems, respectively [111,227]. Although COUP-TFs are classified as 
orphan receptors, as they have no currently established physiological ligands, the crystal 
structure of the COUP-TFII LBD showed that its "auto-repressed conformation" was 
relieved by 9-cis and all-trans retinoic acids (9cRA and atRA) that bind the LBO with -
17-26 ~M affinity [120]. 
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While the precIse gene changes and epigenetic events that lead to breast 
tumorigenesis are still under investigation [228-230], estrogens are well-established risk 
factors in breast cancer [231]. Adjuvant endocrine therapies including the use of 
antiestrogens, e.g., tamoxifen (TAM), and aromatase inhibitors (AI), e.g., letrozole, are 
effective in reducing disease recurrence in many patients [102]. Antiestrogens, including 
TAM and fulvestrant, work by targeting estrogen receptor a (ERa) because of its 
proliferative activity in breast tumors [232,233]. AI work by blocking the synthesis of 
estrogens from androgenic precursors including androstenedione and testosterone [234]. 
Altered gene expression can dictate both the formation of tumors and patient 
response to treatment. In breast cancer, conflicting evidence has been reported on the 
nature of COUP-TFII in either promoting or inhibiting cancer formation, as well as 
influencing patient survival with adjuvant therapy. COUP-TFII is not expressed in basal-
like, triple negative, dedifferentiated MDA-MB-231 and is lower in tamoxifen 
(T AM)/endocrine-resistant LCC9 and LY2 breast cancer cells than in parental endocrine-
sensitive MCF-7 cells, whereas COUP-TFI expression is similar [116], suggesting a role 
in maintenance of differentiation and endocrine sensitivity. In agreement with this data, 
COUP-TFII was reduced in some ERa-null breast cancer cell lines [167]. These results 
suggest that, like ERa, loss of COUP-TFII may be considered an indicator of poor 
prognosis. Other reports suggested that COUP-TFII may playa role in mammary tumor 
formation in mice and that COUP-TFII expression in human breast tumors is associated 
with reduced survival [206,209]. These conflicting findings may be resolved through 
further investigation of the activities of COUP-TFII in breast cancer. 
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The function of COUP-TFs as transcription factors that can either suppress or 
stimulate gene transcription is dependent on interactions with other proteins. COUP-TFI 
[127] and COUP-TFII [119] interact with corepressors NCoR and SMRT. Proteins 
interacting with COUP-TFI include Sp1 [235]; the viral transactivator Tat [236]; CTIP1 
and CTIP2, HDACs 1 and 2, and a nucleosome remodeling and deacetylation (NuRD) 
complex [237]; ERa [130,238]; AhR [239]; and many coregulators (reviewed in [156]). 
Twenty-four proteins interacted with HA-FLAG-COUP-TFI in stably-transfected 
HeLaS3 cells [114]. Interaction of ORCA with the COUP-TFII LBD stimulated 
transcriptional activation of the rat hydratase-dehydrogenase gene promoter in transiently 
transfected Bsc40 monkey kidney cells [123]. COUP-TFII interacted with the hinge 
domain of the glucocorticoid receptor a (GRa) and repressed phosphoenolpyruvate 
carboxykinase gene transcription [124]. No one has, to our knowledge, reported 
proteomic identification of COUP-TFII-interacting proteins. 
The focus of the present study was to identify proteins that interact with COUP-
TFII in MCF-7 cells to gain new insights into COUP-TFII' s role in breast cancer. 
Nucleolin was identified among the nuclear proteins interacting with COUP-TFII. 
COUP-TFII-nucleolin interaction was confirmed by co-immunoprecipitation. This study 
reports a significant inverse association of COUP-TFII with breast tumor grade. 
Expression of the tumor suppressor retinoic acid receptor P2 (RARP2), reduced in breast 
cancer [240,241], and dependent on COUP-TFII [118] was increased by nucleolin 
overexpression. Our data indicate that nucleolin plays a coregulatory role in COUP-TFII 
transcriptional regulation of RARB2. 
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MATERIALS AND J\IlETHODS 
Chemicals 
4-hydroxytamoxifen (4-0HT) and 9-cis and all-trans retinoic acid (9cRA and 
atRA) were from Sigma (St. Louis, MO). ICI 182,780 (Fulvestrant) was from Tocris 
(Ellisville, MO). Sequences of AS 141 1 (AGRO 100, an antiproliferative, 26-mer G-rich 
oligonucleotide) and an inactive negative control C-rich control oligonucleotide (CRO) 
were reported [242] and purchased from Integrated DNA Technologies, Inc. (Coralville, 
JA). 
Antibodies and reagents 
The following antibodies were purchased: polyclonal COUP-TFII (Abcam, 
Cambridge, MA); monoclonal (mAB) anti-human COUP-TFII (R&D systems, 
Minneapolis, MN; PP-H7147-00. 2ZH7147H); mAB anti-FLAG M2 and ~-actin 
(Sigma); polyclonal nucleolin (NB600-241, Novus Biologicals, Littleton, CO), 
monoclonal nucleolin/C23 (MS-3; Santa Cruz Biotechnology, Santa Cruz, CA); MBP-
probe (R3.2; Santa Cruz Biotechnology); and HDAC-l (Santa Cruz Biotechnology). 
HRP-conjugated secondary antibodies were from GE Healthcare (Piscataway, NJ). 
Goat anti-rabbit and anti-mouse magnetic beads were from Thermo Scientific 
(Waltham, MA). In vitro transcription/translation used PROTEINScript II kit (Ambion, 
Austin, TX) or TNT Quick Coupled Transcription/Translation (Promega, Madison, WI). 
Plasmid construction 
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Human COUP-TFII cDNA was amplified from DNA from MCF-7 cells using Pfx 
DNA polymerase (Invitrogen, Carlsbad, CA). The forward primer contained an EcoRI 
restriction site (5'-CCGAATTCGATATGGCAATGGTAGTTAGCACG-3') and the 
reverse primer was designed to remove the stop codon from COUP-TFII and add a XhoI 
restriction site (5'-GTCCTCGAGTCGTTGAATTGCCATATACGGCCA-3'). The 
resulting fragment was cloned into pIRES-GFP-1a (Stratagene, Santa Clara, CA) to 
constmct a C-terminal FLAG-tagged COUP-TFII expression plasmid (pIRES-COUP-
TFII-FLAG). The inclusion of COUP-TFII-FLAG in the resulting pIRES-COUP-TFII-
FLAG plasmid was verified by DNA sequencing and western blot analysis (Appendix I, 
Figure Sl). 
Cell culture 
MCF-7 and T47D breast cancer cells were purchased from ATCC and used at 
passage < 10. T47D were grown in RPMI 1640 (Invitrogen) supplemented with 5% FBS 
and 61lg/ml insulin (Sigma). MCF-7 cells were maintained as described [116]. 
Affinity purification and identification of COUP-TFII-FLAG interacting proteins 
One mg of whole cell extract (WCE), prepared as described in [116], from MCF-
7 cells transfected (24 h) with pIRES-COUP-TFII-FLAG as described in Methods Sl 
(Appendix I) was incubated with EZ view™ Red ANTI-FLAG® M2 Agarose Affinity 
gel (Sigma) overnight (-16 h) at 4°C with constant rotation. COUP-TFII-FLAG 
interacting proteins were eluted using two methods: 1) 0.1 M glycine, pH 3.5, 15 min at 
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room temperature with constant rotation; 2) an additional incubation with 0.1 M glycine, 
pH 3.5, 5 min at 95°C (Appendix I, Fig. S2A). 
Protein identification by multidimensional protein identification technology (MudPIT) 
Proteins eluted from the FLAG-affinity gel were trypsin digested and processed 
for mass spectrometry as detailed in Methods S 1 (Appendix I). MSIMS spectra of the 
peptides were acquired by Q-TOF mass spectrometer (Waters, Milford, MA) in data 
dependent mode. Proteins were identified by comparing MS/MS spectra with sequences 
in Swiss-Prot database by ProteinLynx from Waters. 
Co-immunoprecipitation (co-IP) and immunoblotting 
Nuclear and cytosolic proteins were harvested in lysis buffer (lOmM HEPES pH 
7.9, 1.5mM MgClz, and lOmM KCI) containing 0.1 M DTT, protease and phosphate 
inhibitors (Roche, Indianapolis, IN). Following centrifugation, the supernatant 
containing cytosolic extract (CE) was collected. The pellet was resuspended in nuclear 
extraction buffer (20 mM HEPES pH 7.9, 1.5 mM MgClz, 0.4 M NaCI, 0.2 M EDTA, 
and 25% (v/v) glycerol), 0.1 M DTT, protease and phosphatase inhibitors. Nuclei were 
disrupted by sonication and the nuclear extracts (NE) were collected after centrifugation. 
For IP, 4 ~g COUP-TFII polyclonal antibody, nucleolin monoclonal antibody, 
rabbit or mouse IgG (Abeam, Santa Cruz) were added to 250 ~l prewashed MagnaBind 
goat anti-rabbit or anti-mouse IgG beads in RIPA buffer (Sigma) containing DTT, 
protease and phosphatase inhibitors for 30 min at 4°C. 200-400 ~g NE was added and 
incubated for 4 h at 4°C. Antibody-bound beads were incubated with buffer without NE 
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as an additional negative control. Beads were washed 2x with RIPA buffer, resuspended 
in 1x Laemmli loading buffer (BioRad, Hercules, CA), separated by SDS-PAGE and 
analyzed by western blot [116]. 
In vitro transcribed-translated COUP-TFII interaction with purified recombinant 
maltose binding protein (MBP)-nucleolinfusion proteins 
Extracts from E. coli expressing MBP-tagged nucleolin constructs, a gift from Dr. 
Nancy Maizels [243], were prepared in column buffer (CB, 20 mM Tris-HCI (pH 7.4), 
0.2 mM NaCI, 1 mM EDTA) with 0.1 mM PMSF. 200 Ilg crude extract was incubated 
with 100 ilL amylose resin (New England Biolabs, Ipswich, MA) for 2 h at 4°C. After 
washing with CB, 20 ilL of in vitro transcribed/translated COUP-TFII (pIRES-COUP-
TFII-FLAG) was added to the amylose resin for 2 h at 4°C. After washing 3x with CB, 
bound proteins were eluted with 50 ilL of 1x Laemmli loading buffer. 
Immunofluorescence staining of COUP-TFII and nucleolin 
MCF-7 cells were grown on culture slides (BD Biosciences, Bedford, MA) and 
fixed with cold methanol. Cells were permeabilized with 0.2% Triton X-100. After 
blocking with 10% BSA in PBS for 1 h, primary monoclonal COUP-TFII (R&D) and 
polyclonal nucleolin (Novus Biologicals) antibodies were added (1:100) for 2 h. The 
cells were stained with secondary anti-mouse antibody labeled with DyLight™ 488 or 
anti-rabbit antibody labeled with rhodamine (TRITC) (Jackson ImmunoResearch, West 
Grove, PA) (1:500). Cells were incubated with Hoechst (2,5'-Bi-1H-benzimidazole, 
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Invitrogen) for 10 min. Images were captured using an Olympus FV1000 confocal 
microscope with a 40x objective lens using FIuo View ™ software. 
Immunohistochemistry of breast tissue microarrays (TMA) 
COUP-TFII and nucleolin immunohistochemistry (IHC) was performed using 
commercial breast tissue microarrays BR961 and BR963 (U.S. Biomax) or an in-house 
TMA constructed following ethical approval from St. Vincent's University Hospital 
Ethics Board with tissue from 332 primary breast patients, following written informed 
consent, as previously described [61,244]. Data on the patients included pathological 
characteristics (tumor size, grade, lymph node status, estrogen receptor status) as well as 
treatment with radiotherapy, chemotherapy or tamoxifen. Follow-up data, median 7.72 
years, was collected on the patients to determine disease free and overall survival. 
Staining was called by two independent observers using the Allred scoring system [61]. 
Xenografted MCF7 and HCT116 tumors were used as positive and negative controls, 
respectively (data not shown). Anti-Nucleolin antibody (Clone 4E2, Abcam) was diluted 
at 1:500 with overnight incubation at 4°C for BR961 and BR963. A metastatic melanoma 
was used as a positive control for nucleolin (data not shown). COUP-TFII and nucleolin 
staining were expressed as H-score: product of intensity (0 to 3 scale, 0 = no expression, 
3 strongest expression) and frequency (fraction positive, 0-100%). 
Statistical Evaluation of IHe 
The univariate associations between COUP-TFII and nucleolin H-scores and 
categorical predictors used the Kruskal-Wallis test [61]. A multiple linear regression 
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model was used to fit with COUP-TFII and nucleolin H-scores against pathology, tumor 
grade, and TNM, classification. The TNM staging system classifies tumors according to 
disease progression based on the tumor size (T), regional lymph node involvement (N), 
and distant metastasis (M). Upon assignment of TNM, tumors can further be designated 
into a condensed grade/stage (I-IV) based on disease severity [245]. Comparisons in the 
ERa-positive invasive ductal carcinoma subset and among TNM classification within 
tumor grades were examined (t-test). Fisher's exact test was used for categorical 
variables to compare two proportions. Kaplan Meier estimates of survival functions were 
computed and the Wilcoxon test was used to compare survival curves. Two-sided P 
values of <0.05 were considered to be statistically significant. 
Transient transfection 
MCF-7 and T47D cells were transfected with a constant amount of total plasmid 
DNA, pcDNA 3.1 (Promega), pCMV-Tag2 (Stratagene), pcDNA 3.1-mCOUP-TFII 
(kindly provided by Drs. Sophia and Ming-Jer Tsai [246]), pCMV2-nucleolin [247] using 
Fugene 6 or HD (Roche) for 24 h prior to treatment with 10 ~M CRO (negative control), 
AS1411, or random oligomer (RO, 5'-GTTCAGCAGTCACGATTCAGTCCAGT-3') for 
6 or 24 h, as indicated. Where indicated, cells were co-treated with 1 ~M atRA or 9cRA 
for 6 h. Transient transfection of MCF-7 cells with the RARB promoter tk-luciferase 
reporter (kindly provided by Dr. Richard M. Niles [248]) and pTK-Renilla (Promega), for 
dualluciferase reporter assays, as described [130] . 
RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR) 
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RNA was extracted from cells using Trizol (Invitrogen) or RNeasy (Qiagen, 
Valencia, CA). The High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) was used to reverse transcribe total RNA. QRT-PCR for RARB2, NCL, 
ESR1, ESR2, GAPDH, and 18S, using Taqman primers and probes as Assays-on-
Demand, was performed in the ABI PRISM 7900 SDS 2.1 (Applied Biosystems, 
Carlsbad, CA). COUP-TFII (NR2F2) and RRIGl [249] mRNA expression was measured 
by QRT-PCR using the SYBR green method and normalized by GAPDH [116]. Analysis 
and fold differences were determined using the comparative CT method. Fold change 
was calculated from the ~~CT values with the formula T:lL'.CT and data are relative to 
EtOH-treated and control vector transfected cells. 
siRNA transfection 
For nuc1eolin, cells were transfected for 48 h with 25 nM (MCF-7) or 10 nM 
(T47D) nuc1eolin Stealth Select RNAi or Stealth RNAi Negative Control (Invitrogen) 
using Lipofectamine RNAiMAX (Invitrogen). For COUP-TFII, MCF-7 cells were 
transfected for 48 h with 100 pmol NR2F2 Silencer Select siRNA (Ambion). Following 
transfection, cells were treated for 6 h with 1 IlM atRA. 
Chromatin immunoprecipitation (ChIP) 
MCF-7 cells were transfected with pIRES-COUP-TFII-FLAG or empty vector for 
24 hand semm starved for 48 h in medium containing 5% dextran-coated charcoal 
stripped FBS (DCC-FBS) (Atlanta Biologicals, Lawrenceville, GA). Cells were treated 
with 1 IlM atRA or EtOH for 1 h before crosslinking with 1 % formaldehyde for 5 min. 
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ChIP was perfonned using MAGnify ChIP (Invitrogen). Lysates were incubated with 
anti-FLAG M2 antibody (Sigma) or mouse IgG (Invitrogen). The following primers 
were used for PCR to amplify the region of the RARB2 promoter containing a COUP-
TFII binding site [118]: F 5'-CAGGGCTGCTGGGAGTTTTTA-3' and R 5'-
GGCATCCCAGTCCTCAAACAGC-3'. Quantitation was performed as described in 
[250]. 
Statistical analysis 
Values are reported as ± SEM. Student's t test was used for comparisons between 
control and treatment. One way ANOV A was used for multiple comparisons followed by 
Student-Newman-Keuls or Dunnett's post-hoc tests using GraphPad Prism. P values 
considered statistically significant are indicated. 
RESULTS 
Identification of COUP-TFII-associated proteins 
C-tenninal FLAG-tagged COUP-TFII was overexpressed in MCF-7 cells (-2-fold 
higher expression compared to COUP-TFII endogenous expression; Appendix I, Fig. S 1 
and S2) and interacting proteins were captured by immunoprecipitation (IP) with anti-
FLAG-affinity gel (Appendix I, Fig. S2A). The negative control was MCF-7 cells 
transfected with the pIRES-GFP-1a parental vector and parallel purification of 
nonspecific interacting proteins (Appendix I, Table S1). The capture of COUP-TFII-
FLAG by the anti-FLAG affinity gel was demonstrated (Appendix I, Fig. S2C). Serial 
glycine steps eluted COUP-TFII-FLAG-associated proteins (Appendix I, Fig. S3). In the 
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first elution, 18 proteins having a 'moderate association' with COUP-TFII including 
hsp70, an established NR chaperone that interacts with COUP-TFI [114], were identified 
(Appendix I, Table S2). The second elution identified 36 more 'strongly associated' 
nuclear proteins, i.e., ribnucleoproteins, histones, DNA repair proteins, and RNA binding 
proteins, and nucleolin (Table 2), reflecting COUP-TFII nuclear localization. 
Nucleolin is a multifunctional protein with roles in processes including 
transcription, ribosome biogenesis, DNA replication, histone chaperone/chromatin 
remodeling, apoptosis, and macropinocytosis [251-254]. There are several examples of 
nucleolin functioning as a transcription factor or as a coregulator through its interactions 
with other proteins [255-257]. Because nucleolin plays multiple nuclear roles and is a 
target of anticancer therapy [252], we selected nucleolin for follow-up studies. 
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Table 2. Identification of COUP-TFII interacting proteins in MCF -7 cells. 
WCE from pCOUP-TFII-FLAG-transfected MCF-7 cells (Fig. 6) was incubated with 
anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 5 min. at 95°C, and 
subjected to MudPIT peptide identification. Matched (No) indicates the number of 
sequenced pep tides that match the full length protein. Coverage indicates the % of the 
total protein matched. (Only matches of> 1 peptide match and/or> 3% coverage are 
included.) 
Protein name Accession Mass pi Matched Coverage 
~GI~ ~Mr~ ~No~ ~%~ 
Histones 
Histone H1.0 P07305 20719 11.2 1 6.7 
Histone H2A type 2-C Q16777 5919 11.8 1 16.1 
Histone H1.4 P10412 21721 11.4 7 4.1 
Proteins involved in cell cycle & 
proliferation 
Antigen KI-67 P46013 358525 9.8 6 0.5 
Regulator of chromosome 
P18754 44941 7.7 4 3.1 condensation 
Poly [ADP-ribose] polymerase 1 
P09874 112881 9.2 7 5.7 (PARP-1) 
Proteins involved in 
transcription 
Activated RNA polymerase II 
P53999 14255 9.9 8.7 transcriptional coactivator p15 
DNA Repair Proteins 
DNA topoisomerase 1 P11387 90669 9.6 5 1.6 
DNA topoisomerase 2-beta 
Q02880 183152 8.4 4 2.0 (Topolll3) 
ATP-dependent DNA helicase 2 
P12956 69668 6.6 3 2.1 subunit 1 
ATP-dependent DNA helicase 2 
P13010 82521 5.7 3 3.0 subunit 2 
Peptidyl-prolyl cis-trans isomerase 
P23284 22728 9.6 3 10.6 B 
RNA binding proteins 
RNA-binding protein FUS P35637 53394 9.5 3 2.7 
Splicing factor, arginine/serine-rich 
Q07955 27597 10.5 4 12.6 1 
Splicing factor, arginine/serine-rich 
Q13242 25526 8.9 2 5.4 9 
Splicing factor, arginine/serine-rich 
Q16629 27350 11.8 2 3.8 7 
Other nuclear proteins 
Nonhistone chromosomal protein 
P051 14 10522 10.0 2 24.2 HMG14 
Nucleolin Protein C23 P19338 76167 4.6 3 1.7 
Heat shock cognate 71 kDa protein P11142 70854 5.4 2 4.3 
GTP-binding nuclear protein Ran P62826 24408 7.6 2 9.7 
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Heat shock 70 kDa protein 1 
(hsp70, HSPA 1) 
P08107 
53 
70009 5.6 2 4.4 
Endogenous COUP-TFII and nucleolin interact in MCF-7 and T47D cells 
We next examined endogenous nucleolin-COUP-TFII interaction in untreated 
MCF-7 cells. IP with a COUP-TFII antibody detected nucleolin interaction in the NE 
(Fig. 6A), although nucleolin is in CE as well (Appendix I, Fig. S4A). We did not detect 
COUP-TFII-nucleolin interaction in CE because COUP-TFII is not in the CE (Appendix 
I, Fig S4A). Reciprocal co-IP of COUP-TFII with nuclear nucleolin was detected 
(Appendix I, Fig. S4A). Another example of a COUP-TFII- nucleolin co-IP in MCF-7 
cells is also provided (Appendix I, Fig. S4C and D). To examine whether COUP-TFII 
interacts with nucleolin in another luminal breast cancer cell line, we performed IP with a 
COUP-TFII antibody in T47D cells and confirmed nucleolin-COUP-TFII interaction in 
the NE (Fig 6B). Immunofluorescence microscopy revealed a pattern of co-localization 
of endogenous nucleolin and COUP-TFII in the nucleus, but not within the nucleolus nor 
in the cytoplasm, of MCF-7 cells (Fig. 6C). These data confirm endogenous COUP-
TFII-nucleolin nuclear interaction. Because the focus of this study is COUP-TFII-
interacting proteins, we did not evaluate COUP-TFI-nucleolin interaction. 
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Figure 6. Endogenous nuclear nucleolin-COUP-TFll interaction in MCF -7 and 
T47D cells. 
NE (200 ~g protein) from MCF-7 cells (A) and (400 ~g protein) from T47D (B) cells 
were immunoprecipitated with COUP-TFII antibody or with rabbit IgG (negative 
control), followed by western blot analysis for nucleolin and COUP-TFII. 5% input NE 
serves as loading control. C, Immunofluorescent staining of endogenous COUP-TFII 
(green) and nucleolin (red) in the nuclei (Hoechst, blue) ofMCF-7 cells. Merged images 
are shown at the right. Bar is 10 ~m. D, schematic representation of the N- terminal 
maltose binding protein (MBP)-tagged recombinant nucleolin proteins used for MBP 
pull-down assays. MBP was fused to the N-termini of the RNA binding domains (RED) 
and/or the arginine/glycine-rich domain (RGG) of nucleolin. E, In vitro 
transcribed/translated COUP-TFII was incubated with the MBP-nucleolin fragments or 
MBP. Interacting proteins were captured with amylose resin. Eluted proteins were 
probed for COUP-TFII (top) and MBP (bottom, control). 
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Direct interaction of CO UP-TFII with the RGG domain of nucleolin 
To determine if COUP-TFII interacts directly with nucleolin and which domain(s) 
are involved, in vitro transcribed/translated COUP-TFII and MBP-tagged recombinant 
nucleolin polypeptides were incubated with an amylose affinity resin (Fig. 6D and E). 
The MBP fusion proteins contain the RNA binding domains (RBDl ,2,3,4) and/or the 
arginine-glycine repeat (RGG). Nine RGG repeats are present in the C-terminus of 
nucleolin. Only these domains were investigated because the N-terminal domain of 
nucleolin cannot be expressed in E. coli [247]. COUP-TFII was bound to all MBP-
tagged polypeptides containing the RGG domain but not with MBP-RBDl,2, MBP-
RBD3,4, or MBP alone. RGG9 appears to interact with COUP-TFII with weaker affinity 
compared to RGG4, perhaps because of the lower abundance of the MBP-RGG9 protein 
relative to MBP-RGG4. Overall, these results indicate that the C-terminal RGG domain 
is the minimal domain required for COUP-TFII-nucleolin interaction. 
Immunohistochemical COUP-TFII and nucleolin staining in human breast tissue and 
tumor tissue microarrays 
Nuclear COUP-TFII and nucleolin immunoreactivity were examined in two 
independent human breast tissue micro arrays (TMAs, Fig. 7). In the TMAs from u.s. 
Biomax, significant differences in COUP-TFII staining were observed between TNM 
classes of tumor grades II (d = -51.7, P = 0.078) and II-III (d = -58.5, P = 0.046) (Fig. 
7C). COUP-TFII and nucleolin staining were correlated in invasive ductal carcinomas 
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(<j>p = 0.31, p=0.0281; <j>s = 0.30, p=0.0334). Normal breast tissue was also positive for 
COUP-TFII expression (Average H-score 127.5, SEM 5; data not shown). In a separate 
breast TMA [61], staining of a total of 332 patient tumors showed -47% were positive 
for nuclear COUP-TFII (Table 3, Fig. 7F). There was a significant association between 
tumor grade and COUP-TFII with high grade tumors tending to be COUP-TFII negative 
(Table 3). COUP-TFII was also significantly positively associated with ERa, SRC-l, 
PEA3, MMP2, and phospho-Src and negatively associated with HER2 (Table 3). High 
SRC-l (NCOA1) was associated with a favorable response to TAM [258], a finding that 
corresponds to COUP-TFII's role in 4-0HT-medicated inhibition of breast cancer cell 
proliferation [116] . However, breast tumors from aromatase inhibitor-resistant patients 
show high expression of SRC-l and a reduction in disease-free survival [259]; thus, the 
relationship between COUP-TFII and SRC-l expression will require further 
investigation. SRC-l and PEA3 synergistically activated COUP-TFII-promoter 
luciferase activity in transiently transfected He La cells [181]. PEA3 directly activates 
MMP2 transcription [244]; hence COUP-TFII may be correlated with MMP2 through the 
PEA3-COUP-TFII connection, although this hypothesis will require further analysis 
beyond the scope of the present study. The relationship between COUP-TFII and 
phospho-Src may be because activation of Src is part of the MAPK pathway that 
increases COUP-TFII expression [183]. According to Kaplan Meier, COUP-TFII did not 
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Figure 7. COUP-TFII and nucleolin in breast cancer tissue microarrays. 
A and B, COUP-TFII immunostaining at 200x: A, benign breast tissue (H-score 30) and 
B, invasive ductal carcinomas, grade 2 (H-score 153), Bar is 200 mm, C, Average ± 
SEM ofH-score for nuclear COUP-TFII staining in ERa-positive invasive ductal 
carcinomas by tumor grade. * significantly different from T2NOMO (p < 0.05). D and E, 
Nucleolin immunostaining at 400x: D, benign breast tissue (H-score 13) and E, invasive 
ductal carcinomas, grade 3 (H-score 151). Bar is 100 J..Lm. F and G, immunohistochemical 
localization ofCOUP-TFII (lOOx, inset: 200x) on a tissue micro array constructed from 
archival tissue from 332 breast cancer patients [61] showing positively (F) and negatively 
(G) stained cores COUP-TFII at 200x, bar is 100 J..Lm. H and I, Kaplan-Meier estimates 
of disease-free survival functions were computed, and the Wilcoxon test was used to 
compare survival curves, In addition, the Wilcoxon rank sum test was used to compare 
two medians. The data are not statistically significant. 
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Table 3. COUP-TFII staining in breast tumor microarray. 
Associated expression of COUP-TFII with ERa, PR, HER2, SRC-l, AIBl, Pea3, AIBl, 
MMP2, and phospho-Src (psrc) staining in 560 human breast tumors [61,244]. Statistical 
analysis was performed using the Fisher's exact test, and a P value of <0.05 is considered 
to be significant (bold values). 
Total % COUPTFII P 
Population positive value 
n=321 47% 
ER 
neg 99 34.3 
~os 222 52.3 0.004 
PR 
neg 133 50.4 
~os 146 44.5 0.339 
Her2 
neg 267 50.2 
~os 62 32.3 0.011 
Grade 
1 24 54.2 
2 122 54.1 
3 112 33.0 0.003 
Node 
neg 156 47.4 
~os 167 46.1 0.824 
Recurrence 
neg 200 46.0 
~os 132 47.7 0.822 
SRC-1 
neg 214 41 .6 
~os 113 56.6 0.011 
AIB1 
neg 88 25.0 
~os 221 55.7 <.001 
Pea3 
neg 120 35.8 
~os 120 58.3 0.001 
MMP2 
neg 29 20.7 
~os 284 48.2 0.005 
psrc 
neg 226 42.0 
pos 87 56.3 0.031 
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atRA enhances COUP-TFII binding to the RARB2 promoter 
COUP-TFII is required for atRA- or 9cRA- induced RARB2 expression in breast 
cancer cells [118,131] and binds the RARB2 promoter in electrophoretic mobility shift 
assays [118]. To examine COUP-TFII interaction with the RARB2 promoter, we first 
examined recruitment of endogenous COUP-TFII to the RARB2 promoter using the R&D 
systems COUP-TFII antibody, but were unable to detect product in the PCR reactions 
(data not shown) likely due to lower COUP-TFII protein in MCF-7 cells compared to 
C3HlOT1I2 CH3 mouse embryo mesenchymal cells that express high levels of COUP-
TFII [260]. To obviate this difficulty, MCF-7 cells were transfected with an empty 
vector or COUP-TFII-FLAG and ChIP was performed after FLAG IP. ChIP revealed for 
the first time that COUP-TFII binds the RARB2 promoter and atRA increased COUP-
TFII occupancy at the RARB2 promoter by 72% in MCF-7 cells (Fig. 8A; Appendix I, 
Fig. S5). 
AS1411 inhibits COUP-TFII-stimulated RARB2 gene expression in MCF-7 and T47D 
breast cancer cells 
Once establishing the presence of COUP-TFII at the promoter of its target gene 
RARB2, we sought to determine if nucleolin functions as a coactivator for COUP-TFII-
mediated RARB2 expression. RARB2 was increased in MCF-7 cells transfected with 
COUP-TFII and nucleolin overexpression potentiated the RARB2 induction in a 
concentration-dependent manner (Fig. 8B). Further, because the G-rich, G-quartet 
forming DNA aptamer AS 1411 binds and reduces nucleolin activity [252,261], we 
hypothesized that AS1411 would inhibit COUP-TFII-stimulated RARB2 expression. 
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AS1411 inhibited the COUP-TFII-induced increase in RARB2, while CRO (negative 
control) had no effect (Fig. SC). Although nucleolin did not affect basal RARB2 
expression, nucleolin abrogated the inhibition of RARB2 transcription by AS1411 (Fig. 
SC). COUP-TFII also increased luciferase activity from a RARB gene promoter-reporter 
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A, ChIP of COUP-TFIl-FLAG to the RARB2 promoter in MCF-7 cells transfected with 
empty vector (EV) or COUP-TFIl (CIl) and treated with EtOH or 1 /lM atRA for 6 h. * 
P < 0.05 versus E control , f P < 0.05 versus CIl-EtOH. B-C, Cells were transfected with 
parental or expression plasmids for COUP-TFIl or nucleolin for 24 h and were treated 
with EtOH, 10 /lM CRO or AS1411 for 24 h post-transfection. For C, cells were 
transfected with 0.5 /lg and 1 /lg of nucleolin and COUP-TFIl expression vector, 
respectively. QRT-PCR was performed to determine RARB2 expression. Values are the 
average of 6 separate experiments ± SEM. D, Cells were transfected with pcDNA or 
pcCOUP-TFIl and treated with 10 /lM RO or AS1411 for 24 h. Dualluciferase activity 
was expressed relative to the pcDNA-transfected, no-treatment control. Values are mean 
± S.E.M. of two separate experiments. For B-D, * P < 0.05 versus vector control, ** 
COUP-TFIl alone, or ... between the indicated values. 
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To be sure that any effect of AS1411 on RARB2 is not cell-line specific, MCF-7 
and T47D cells with similar nucleolin expression (Appendix I, Fig. S6) were tested. 
T47D has -40% lower COUP-TFII than MCF-7 (Appendix I, Fig. S6). Both atRA and 
9cRA increased RARB2 expression in MCF-7 and T47D cells, with greater induction in 
T47D, and increased NR2F2 (COUP-TFII) expression in T47D (Fig. 9A-B). 
Pretreatment of MCF-7 cells with AS1411, but not negative control CRO, 
reduced atRA-induced RARB2 expression (Fig. 9C). Transfection of MCF-7 cells with a 
nucleolin expression vector increased basal RARB2 except in AS1411-treated cells. 
Nucleolin and atRA additively increased RARB2 expression in MCF-7 cells and AS1411, 
but not CRO, reduced RARB2 induction. Nucleolin significantly abrogated the inhibition 
of RARB2 expression by AS1411. COUP-TFII mRNA levels were not significantly 
reduced by AS1411 (Appendix I, Fig. S7). Neither ER antagonists ICI 182,780 nor 4-
ORT blocked atRA-induced RARB2 expression, indicating that ER is not involved in 
COUP-TFII-activated RARB2 expression (Fig. 9C). ICI and 4-0RT increased basal 
RARB2 in MCF-7, in agreement with RARB-Iuciferase reporter activation in transfected 
MCF-7 cells [262]. 
Pretreatment of T47D cells with AS1411, but not CRO, reduced atRA-induced 
RARB2 expression and co-transfection with an expression vector for nucleolin 
significantly abrogated the inhibition of RARB2 expression by AS1411 (Fig. 9D). 
AS1411 had no effect on MCF-7 cell viability for the treatment times used in these 
experiments (Appendix I, Fig. S8), commensurate with previous findings that MCF-7 
viability is inhibited only after 6 d of AS1411 treatment [261]. 
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Figure 9. Regulation of RARP2 transcription. 
** ** 
* * * 
+ - +++--++ 
+ + + + 
A and B, QRT-PCR for RARB2 (B RAR~2) and NR2F2 (C COUP-TFII) in MCF-7 or 
T47D cells treated with EtOH, 1 !J.M atRA, or 1 !J.M 9-cis-RA for 24 h. Values are the 
average of 3-5 separate experiments. * P < 0 .05 versus EtOH. C, MCF-7 and D, T47D 
cells were transfected with 2 !J.g pCMV -tag2 (-) or pCMV -tag2-nucleolin (+) for 24 h 
prior to 24 h treatment with EtO H, 10 !J.M CR 0 , or 10 !J.M AS 14 11. Where indicated, 
cells were treated with 1 !J.M atRA, 100 nM 4-0HT, or 100 nM ICI 182,780 for 6 h. 
QRT-PCR for RARB2 expression. Values are the average of 6 (MCF-7) and 4-10 (T47D) 
separate experiments ± SEM. * P < 0 .05 versus EtOH or ** between the indicated 
values. 
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RARB2 expression is inhibited by nucleolin or COUP-TFII knockdown 
siNucleolin reduced nucleolin (NCL) mRNA by 37-58% and protein by 22-35% 
(Fig. lOA) in MCF-7 cells. In parallel, basal RARB2 was reduced 32-56% (Fig. lOA). 
To determine if nucleolin knockdown inhibited atRA-induced RARB2, T47D cells were 
transfected with siNucleolin and untreated or treated with atRA (Fig. lOB). atRA had no 
effect on nucleolin knockdown (Fig. lOB). Analogous to the MCF-7 cells, siNucleolin 
reduced RARB2 rnRNA (Fig. lOB). siNucleolin inhibited the atRA induction of RARB2 
-36%. Taken together, results from AS1411 and siNucleolin studies indicate a functional 
role for nucleolin as a coactivator of COUP-TFII-regulated atRA-induced RARB2 
expression in T47D and MCF-7 cells. 
siCOUP-TFII reduced COUP-TFII protein and, consequently, RARB2 
transcription and protein (Fig. 10C). RAR~2 stimulates retinoic acid receptor-induced 
gene 1 (RRIG1) transcription [263] . siCOUP-TFII reduced basal and atRA-induced 
RRIGl expreSSIOn. Transfection with COUP-TFII increased RRIG1. These data 
substantiate COUP-TFII' s regulation of functional RAR~2. 
Effects of AS1411 on nucleolin-COUP-TFII nuclear interaction 
AS 1411 reduced the nuclear/cytoplasmic ratio of the nucleolin-interacting protein 
PRMT5 (Protein Arginine Methyltransferase 5) in DU145 prostate cancer cells [247]. 
AS1411 or CRO did not change nuclear COUP-TFII or nucleolin or cytosolic nucleolin 
in MCF-7 cells (Fig. llA-B). There was no change in relative COUP-TFII-nucleolin 
interaction in MCF-7 cells treated with AS 1411 (Fig. 11 C- D). 
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Figure 10. Reduction of COUP-TFII or nucleolin decreases RAR~2 transcription in 
MCF-7 cells. 
MCF-7 (A) and T47D (B) cells were transfected with control siRNA or an siRNA 
targeting nucleolin for 48 h. T47D cells were treated with EtOH or 1 flM atRA for 24 h. 
QRT-PCR for nucleolin (NCL) and RARB2. Values are the average of triplicates. C, 
Western blot showing COUP-TFIl and RAR~2 expression after transfection with 
siCOUP-TFlI. Values are relative to ~-actin . MCF-7 were transfected with siControl or 
siCOUP-TFII for 48 h and treated with 1 flM atRA for 6 h. QRT-PCR was also 
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Figure 11. Effects of AS1411 on nuclear nucleolin-COUP-TFII interaction. 
A, Representative western blots of CE and NE (30 /lg) from MCF-7 cells: untreated 
(untx) or treated with 10 /lM CRO or AS1411 for 24 h were probed for nucleolin or 
COUP-TFII , then stripped and reprobed for HDAC1 and a-tubulin. B, Relative 
nucleolin and COUP-TFII expression (normalized to respective loading controls and 
lmtreated sample protein ratios were set to 1 for NE and CE). Bars are the mean ± SEM 
of 4-8 separate experiments. C, NE or CE (200 /lg) from MCF-7 cells treated as above 
were IPed with COUP-TFII antibody or rabbit IgG. The Ab-no NE lane was a negative 
control: COUP-TFII antibody incubated with beads and buffer without NE. D, The ratio 
of nuclear nucleolinfCOUP-TFII is the mean ± SEM of 3 experiments. 
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DISCUSSION 
COUP-TFII plays an undefined role in breast cancer [116]. In this report, we 
identify nucleolin as a new functional partner for COUP-TFII. We have demonstrated for 
the first time that COUP-TFII binds nucleolin in vitro and in vivo. In breast tumors, 
nuclear nucleolin correlates with ERa and cell proliferation [264,265]. Here mc 
staining revealed a correlation between nuclear COUP-TFII and nucleolin staining in 
invasive ductal carcinoma, a finding that reflects a previous report showing 
overexpression of COUP-TFII in A549 lung adenocarcinoma cells increased in vitro 
tumorigenicity and migration [211]. We demonstrate that nucleolin acts as a coactivator 
of endogenous COUP-TFII transcriptional activity for RARB2 in breast cancer cells. 
Similarly, nucleolin acted as a coregulator by interacting with c-Jun and Spi and 
increasing cytosolic phospholipase A2 (cPLA2) gene transcription [256]. 
We report a positive correlation between COUP-TFII and ERa, SRC-I, Pea3, 
MMP2, and phospho-Src expression, an inverse correlation of COUP-TFII with tumor 
grade and reduced COUP-TFII in ERa-positive, invasive ductal carcinomas with 
increased TNM stage within tumor grades II and III and HER2 positivity. These data are 
in agreement with Oncomine analysis demonstrating NR2F2 is higher in ERa+ tumors 
and lower in metastatic breast tumors in microarray data [266] (Appendix I, Fig. S9). 
These observations indicate that COUP TFII may playa role in "phenotype maintenance" 
and that its ftffiction may be restricted to the luminal breast cancer subtypes. We 
speculate that the precise role of COUP-TFII in breast cancer depends on cellular context, 
which is consistent with the role of other nuclear receptors in breast cancer [267], and 
remains to be fully elucidated. 
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Other COUP-TFII-interacting proteins identified here include PARP-l, which 
also interacts with nucleolin [268], TOPOIIP, involved in transcriptional activation by 
NRs [269,270], and DNA topoisomerase I (Topol), which localizes to active transcription 
sites [271]. Reflecting its NR chaperone role and interaction with COUP-TFI [114], 
Hsp70 interacted with COUP-TFII. Other COUP-TFII-interacting proteins including 
hnRNP A2/B1, RPS20, RPL15, and RPL21 were also identified as binding with 
nucleolin to a c-myc G-quadmplex affinity column [272]. 
Nucleolin is a key target of the anticancer aptamer AS 1411, although AS 1411 
interacts with other proteins, e.g. , NEMO to inhibit NFKB activation and PARP-1 [252]. 
AS1411 has pleiotropic effects on nucleolin, e.g., inhibiting nucleolin binding to the AU-
rich element in the 3' UTR of BeL2 in MCF-7 cells causing apoptosis [273] and 
stimulating macropinocytosis [251]. AS1411 is used to functionally inhibit nucleolin 
[274]. Here, AS1411 and siNucleolin reduced COUP-TFII-induced RARB2 expression in 
MCF-7 and T47D cells and cotransfection with nucleolin reduced AS 1411-inhibition. 
AS1411 did not alter nuclear COUP-TFII-nucleolin interaction, indicating that the 
mechanism for AS 141.1 inhibition of RARB2 expression is independent of reducing 
nuclear COUP-TFII protein, a result different from AS1411 reducing nuclear PRMT5 in 
DU145 cells [247]. The inhibition of atRA- and COUP-TFII- regulated RARB2 
expression by AS 1411 may also be independent of its effect on nucleolin and may 
indicate a potential adverse 'side effect' of AS1411 that may be a concern if this dmg is 
used for breast cancer therapy. 
In conclusion, COUP-TFII interacting proteins were identified in MCF-7 breast 
cancer cells. Endogenous COUP-TFII and nucleolin interact in both MCF-7 and T47D 
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luminal breast cancer cells. A coregulatory role for nucleolin in COUP-TFII-mediated 
RARB2 transcription was described (Fig. 12). Retinoids, e.g. 9cRA and atRA, and RAR~ 
have long been associated with tumor suppressive properties such as reduced cell 
proliferation, inflammation, and solid tumor formation, as well as enhanced apoptosis 
(reviewed in [275]). RAR~2 expression is reduced in breast tumors and restoration of 
RAR~2 expression increases sensitivity to tumor growth inhibition by retinoids [276]. 
Ours is the first demonstration that atRA increased COUP-TFII-RAR,82 promoter 
interaction by ChIP. Since serum carotenoids levels are inversely associated with breast 
cancer risk in women with high mammographic density [277], the increase in RARB2 in 
response to COUP-TFII-nucleolin interaction is consistent with a role for COUP-TFII in 
phenotype maintenance. In agreement with a previous report [118], we observed a much 
higher induction of RARB2 in T47D in response to atRA compared to MCF-7 despite, as 
newly reported here, lower COUP-TFII expression. These data indicate that other 
mechanisms are also involved. COUP-TFII protein staining in TMAs correlates with 
ERa expression and an inverse correlation of COUP-TFII with tumor grade in ERa-
positive, invasive ductal carcinomas was detected, a finding that correlates with reduced 
COUP-TFII expression in endocrine-resistant breast cancer cells [116]. Together, these 
data suggest that COUP-TFII may be important in differentiated ERa-expressing, 
retinoid-responsive, epithelial breast cancer cells and that reduced COUP-TFII leads to 




Figure 12. Model of nucleolin-COUP-TFII interaction and upregulation of RARB2 
expression. 
COUP-TFII binds its response elements as either a homodimer or as a heterodimer with 
RXR [107] . Previous reports demonstrated that 1) 9cisRA and atRA bind COUP-TFII 
and increase COUP-TFII transcriptional activity [120] ; 2) Nucleolin acts as a 
transcriptional coregulator by interacting with cJun and Spl [256]; 3) COUP-TFI and 
COUP-TFII increase RARB2 expression in cooperation with RARa and CBP [118]. Here 
we demonstrated that 1) nucleolin interacts directly with nuclear COUP-TFII; 2) atRA 
and 9-cisRA increased RARB2 rnRNA; 3) AS1411 , used as a functional inhibitor of 
nucleolin [252,274], inhibited COUP-TFII-upregulation of RARB2 gene transcription; 4) 
siRNA knockdown of nucleolin reduces induction of RARB2 and reduced RAR~2 
protein. 
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CHAPTER IV - COUP-TFII INIDBITS NFlCB ACTIVATION IN BREAST 
CANCER CELLS AND RESTORES ENDOCRINE SENSITIVITY 
INTRODUCTION 
Selective estrogen receptor modulators (SERMs) such as tamoxifen (TAM) exert 
antiproliferative effects on breast cancer by competing with estrogens for binding to 
estrogen receptor a (ERa), leading to an inhibition of downstream genes, including those 
involved in breast cancer proliferation. Fulvestrant is a selective ERa downregulator 
(SERD) because it causes proteasomal degradation of ERa in addition to its SERM-like 
ability to antagonize estrogen-activated ERa transactivation [278]. T AM inhibits cell 
cycle progression and induces apoptosis [45,46]. TAM has greatly increased the survival 
rate of breast cancer patients since its initial FDA approval in 1977, resulting in a 31 % 
reduction in annual death rate [48,279]. Despite the initial efficacy of SERM and 
aromatase inhibitor treatment, approximately 40% of patients relapse and die from 
metastatic disease because the cancer cells become refractory to endocrine therapies [56]. 
The mechanisms for acquired endocrine resistance are complex and a better 
tmderstanding of maintenance of endocrine sensitivity is clearly needed. Reduced 
expression of the orphan nuclear receptor chicken ovalbumin upstream promoter 
transcription factor II (COUP-TFII) has a demonstrated role in acquired endocrine 
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resistance In a breast cancer cell line model of human disease progression [116] . 
Restoration of COUP-TFII expression, which is reduced in endocrine-resistant breast 
cancer cell lines, inhibited cell proliferation and motility and increased apoptosis in TAM 
and fulvestrant-treated endocrine-resistant LCC9 and LY2 breast cancer cells [116]. 
Conversely, inhibition of COUP-TFII expression caused MCF-7 cells to become resistant 
to SERM and fulvestrant inhibition of proliferation [116]. A mechanism for the 
involvement of COUP-TFII in maintenance of endocrine sensitivity has not yet been 
determined. Since COUP-TFII acts as either a transcriptional activator or repressor in a 
gene- and cell-specific manner [226] , the mechanism of action may involve modulation 
of specific target genes including tumor suppressors and oncogenes. 
The NFKB family of dimeric transcription factors has important functions related 
to immune and inflammatory responses, and recent studies have demonstrated NFKB 
activation plays a role in acquired endocrine-resistant breast cancer [87,88,280]. Inactive 
NFKB is located in the cytoplasm bound to IKB , the inhibitor of NFKB. Also present in 
the cytoplasm is the IKK complex containing the regulatory subunit NEMO (nuclear 
factor-KB essential modulator or IKKy) and the catalytic subunits IKKa and IKK~. Upon 
activation by a variety of stimuli, the IKK complex phosphorylates the inhibitor IKB 
leading to its degradation, freeing the now activated NFKB to trans locate to the nucleus to 
regulate target gene transcription. Because NFKB activation results in expression of 
genes that lead to anti-apoptotic and pro-proliferative activities, increased NFKB 
signaling promotes cancer cell survival [281]. 
Dysregulation of the NFKB subunits p65 (RELA), RelB (RELB) , pSO (NFKB1), 
pS2 (NFKB2) , and c-Rel (REL) results in altered activation of the NFKB pathway in 
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breast cancer. Increased expression of pSOINFKBl, pS21NFKB2, and c-Rel was detected 
in breast tumors compared to adjacent normal tissue [282]. Elevated pSO/NFKBl-DNA 
binding correlated with metastatic relapse and reduced disease-free survival in patients 
with ERa-positive tumors [283]. An increase in NFKB activity has been reported in 
endocrine-resistant breast cancer cells [87,280,284]. The amount of RelAlp6S protein 
was also elevated [87]. The expression and DNA binding of pSO and p6S are also 
enhanced in LCCl estrogen-independent, TAM-sensitive breast cancer cells compared to 
MCF-7 estrogen-dependent cells, further demonstrating a role for NFKB in the pathway 
to endocrine resistance [93]. 
Since COUP-TFII expression is decreased in endocrine-resistant breast cancer 
cells, we hypothesized COUP-TFII may playa part in the normal suppression of NFKB 
activity in endocrine-sensitive breast cancer cells by regulating the transcription of 
components of the NFKB pathway. In this study, we observed that COUP-TFII 
overexpression inhibited NFKB activity in LCC9 endocrine-resistant breast cancer cells. 
This suppression of the NFKB pathway resulted in reduced expression of downstream 
NFKB target genes as well as NFKB subunits and increased sensitivity to 4-
hydroxytamoxifen (4-0HT) treatment. Our results provide a mechanism by which 
COUP-TFII maintains endocrine sensitivity by suppressing NFKB expression and activity 
in breast cancer cells. 
MATERIALS AND METHODS 
Chemicals 
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4-hydroxytamoxifen (4-0HT) and BMS-345541 were purchased from Sigma-
Aldrich (St. Louis, MO). Tumor necrosis factor a (TNFa) was purchased from 
PeproTech (Rocky Hill, NJ). 
Antibodies 
The following antibodies were purchased: monoclonal (mAb) anti-human COUP-
TFII (R&D systems, Minneapolis, MN); polyclonal RelAlp65, polyclonal and mAb 
RelB, and mAb NFKB 1 p105/p50 (Santa Cruz Biotechnology, Santa Cruz, CA); 
polyclonal c-Rel, polyclonal NFKBI p105/p50, and polyclonal NFKB2 p100/p52 (Cell 
Signaling, Danvers, MA), ~-actin (Sigma-Aldrich). HRP- conjugated secondary 
antibodies were from GE Healthcare (Piscataway, NJ). 
Cell culture and transient transfection 
MCF-7 cells were purchased from A TCC and used at passage < 10. LCC9 cells 
were kindly provided by Dr. Robert Clarke [285]. MCF-7 and LCC9 cells were 
maintained as in [116]. Cells were transiently transfected as indicated in figure legends 
using FuGENE HD (Roche, Indianapolis, IN) as per the manufacturer's protocol. 
Luciferase assay 
To analyze NFKB activity, MCF-7 and LCC9 cells were transiently transfected 
with pGL4.32[luc2PINF-KB-RE/Hygro] (Promega, Madison, Wn containing five copies 
of a NFKB response element, pGL4-hRluc-TK (Renilla, Promega), and pcDNA3.1 or 
pcDNA3.1 -mCOUP-TFII (kindly provided by Drs. Sophia and Ming-Jer Tsai [246]) for 
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48 h before performing dual luciferase assay (Promega). Where indicated, cotransfection 
was performed with plasmids for CBP (kindly provided by Dr. Margarita Hadzopoulou-
Cladaras [286]), SRC-l (kindly provided by Dr. Bert W. O'Malley [287]), GRIPlISRC-
2, or ACTRlSRC-3 (kindly provided by Dr. Michael Stallcup [288]). 
NF KB pathway peR array 
LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-mCOUP-TFII for 24 
h before treating with 10 ng/ml TNFa for 6 h. RNA was isolated using RNeasy (Qiagen, 
Valencia, CA) and cDNA was prepared usmg RT2 First Strand Kit 
(SABiosciences/Qiagen, Valencia, CA). Human NFKB Signaling Pathway PCR Array 
(SABiosciences/Qiagen) was run according to manufacturer's instructions. 
Electrophoretic mobility shift assay (EMSA) 
MCF-7 and LCC9 cells were transfected with pcDNA3. 1 or pcDNA3.1-mCOUP-
TFII for 48 h followed by treatment with 10 ng/ml TNFa for 6 h. Following 
centrifugation, cells were resuspended in 10 mM HEPES, 1.5 mM MgClz, 10 mM KCl, 1 
mM dithiothreitol (DTT, Sigma-Aldrich), IX protease and phosphatase inhibitors 
(Roche). The cells were lysed with a 27 gauge syringe and centrifuged to obtain 
cytosolic extract. The resulting nuclear pellet was resuspended in EMSA buffer (10 mM 
Tris HCI, 150 mM KCI, 0.5 mM EDTA, 0.1% Triton-X 100, 12.5% glycerol, pH 7.9 
(Sigma-Aldrich), 1 mM DTT, IX protease and phosphatase inhibitor (Roche)) and 
sonicated to prepare nuclear extract (NE). 
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NFKB sense (S'-AGT TGA GGG GAC TTT CCC AGG C-3') and antisense (S'-
GCC TGG GAA AGT CCC CTC AAC T-3 ' ) oligonucleotides (Integrated DNA 
Technologies, Coralville, IA) were annealed and labeled with e2p]-yATP (PerkinElmer, 
Waltham, MA) using T4 polynucleotide kinase (Promega) to prepare labeled DNA probe. 
The e2p]NFKB response element (RE) probe was purified using the QIAquick 
Nucleotide Removal Kit (Qiagen). 
25 ug NE from the indicated cells was incubated with poly-dldC (Sigma-Aldrich), 
e2p]NFKB-RE (labeled probe), and EMSA buffer for 1 h before separating on a 4% non-
denaturing polyacrylamide gel (Bio-Rad, Hercules, CA). For in vitro binding assay, in 
vitro transcribed/translated COUP-TFII was prepared as described in [l1S] and incubated 
in increasing concentrations with NE from LCC9 cells treated with 10 ng/ml TNFa for 6 
h. 
NF T<iJ family transcriptional assay 
MCF-7 or LCC9 cells were transfected with pcDNA3.1 or pcDNA3. 1-COUP-
TFII for 48 h and treated with 10 ng/ml TNFa for 6 h before preparing NE. 15 /-lg NE 
was used for TransAM NFKB assays (Active Motif, Carlsbad, CA) according to the 
manufacturer's protocol. Briefly, NE was added to 8 well strips containing immobilized 
NFKB RE oligonucleotide. Primary antibodies specific for NFKB subunits RelB, ReIA, 
pSO, pS2, and c-Rel were used to identify subunit-specific NFKB activation. Secondary 
HRP-conjugated antibody and provided buffers provided colorimetric quantitation via 
spectrophotometric analysis at 450 nm. 
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Coimmunoprecipitation 
Nuclear extracts were prepared from MCF-7 cells as in [U5]. Dynabeads protein 
A (Life Technologies, Carlsbad, CA) were incubated with COUP-TFII antibody (Abcam, 
Cambridge, MA) or negative control IgG (Santa Cruz) for 30 minutes prior to the 
addition of 400 /J.g MCF-7 NE for 4 h at 4 °c with rotation. Following washes, protein 
was eluted with Elution Buffer (Life Technologies, Carlsbad, CA) and pH was adjusted 
with 1M TrisHCl. 
Cell proliferation assay 
MCF-7 and LCC9 cells were grown for 48 h in medium containing 5% charcoal-
stripped fetal bovine serum (CSS) and transfected with pcDNA or pcDNA-mCOUP-TFII 
for 24 h before treatment with 1 /J.M 4-0HT, 10 nglml TNFa, and 0.01-5 !J.M BMS-
345541 in DMSO for 5 days. Cell proliferation was assayed using CellTiter AQueous 
One Solution Cell Proliferation Assay (MTS; Promega). 
RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR) 
RNA isolation, RT-PCR, and QRT-PCR were performed as ill [U5] . The 
following SYBR green primers were used for QRT-PCR analysis, relative to GAPDH 
control: RELB [289], REL, NFKBl and NFKB2 [290], IL6 [291], A20fl'NFAlP3 [292], 
ICAMl [293], CCL2 [294], NR2F2 and GAPDH [183], Nr2j2 (Forward 5'-
CCCCCATAGATATGGCAA TGGTAGTCAGCACG-3', Reverse 5'-
TTGATTTATTTATTGAATTGCCATATATGGCC-3'). p65/RELA was measured using 
TaqMan Gene Expression Assay (Applied Biosystems) relative to 18S control. 
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Microarray analysis 
Published micro array data was obtained from Gene Expression Omnibus (GEO) 
(dataset GSEI770S) consisting of 298 ERa+ patients treated with tamoxifen for S years 
and analyzed to assess the correlation between COUP-TFII (NR2F2) expression and 
NFKB subunit (NFKB1, NFKB2, REL, RELA, RELB) and target gene (lCAM1, 1L6, 
CCL2, TNFAIP3) expression. Gene expression data was log2 transformed and quantile 
normalized prior to analysis. Correlation analysis was performed using the Spearman 
Rho (pS) statistic to assess whether NR2F2 expression was inversely correlated with 
NFKB subunit/target genes. 
Statistical analysis 
Statistical analyses were performed as in Chapter III [lIS]. 
RESULTS 
COUP-TFII suppresses NF!d3 activity 
To determine if NFKB activity is differentially regulated by COUP-TFII in 
endocrine-sensitive versus -resistant cells , MCF-7 (sensitive) and LCC9 (resistant) cells 
were transfected with a luciferase reporter containing five tandem repeats of a NFKB 
responsive element as well as pcDNA3.1 parental plasmid or pcDNA3.1-COUP-TFII 
(Fig. 13A). Basal NFKB activity in LCC9 is -S fold higher than MCF-7 cells. When 
treated with TNFa, a dramatic induction of NFKB activity is observed in LCC9 but not 
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MCF-7 cells. A statistically significant, dose-dependent decrease in the TNFa-induced 
NFKB activation occurs in LCC9 cells upon transfection with increasing amounts of 
COUP-TFII. These data demonstrate that COUP-TFII suppresses NFKB activity in 
endocrine-resistant breast cancer cells. The expression of NFKB subunits NFKB2, REL, 
and RELB was higher in LCC9 compared to MCF-7 cells (Fig. 13B), accounting for the 
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Figure 13. COUP-TFII suppresses NFlCB activity in LCC9 cells. 
(A) MCF-7 and LCC9 cells were transfected with a NFKB luciferase reporter and 
increasing concentrations of pcDNA3. 1 or pcDNA3.1-COUP-TFII for 48 h and treated 
with 10 ng/ml TNFu for 6 h before performing dualluciferase assay (Promega). Firefly 
luciferase values are shown relative to protein concentration for a representative 
experiment of quadruplicate values ± SEM. * Significantly different P<O.05 from 
pcDNA+ TNFu in LCC9. (B) Comparison of NFKB subunit mRNA expression in MCF-7 
versus LCC9 cells . Values are the mean of 4-8 separate experiments ± SEM. *: P<O.05 
versus MCF-7. 
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Identification ofCOUP-TFII effect on NFKB pathway 
An NF1d3 pathway PCR array was used to determine the effect of COUP-TFII on 
the NF1d3 pathway in LCC9 endocrine-resistant cells treated with TNFa using a 3-fold 
cutoff (Fig. 14A). As displayed in the resulting heatmap, a general decrease in the 
expression of NF1d3 pathway genes was detected upon COUP-TFII overexpression (Fig. 
14B). Many genes suppressed by COUP-TFII greater than 3-fold were NF1d3 -
responsive genes, e.g., CCL2, IL6, LTA, ICAMI, and TNFAIP3, as well as NF1d3 subunits 
(RELB) , reflecting a role for COUP-TFII in downregulation of the NF1d3 pathway. 
These genes were selected for further analysis. 
COUP-TFII suppresses NFKB target gene expression 
To extend and confirm the results from the NF1d3 pathway PCR array, MCF-7 
and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII and treated 
with TNFa to determine the effect of COUP-TFII on endogenous NF1d3 target gene 
expression. COUP-TFII expression following transient transfection was verified via 
western blot (Appendix I, Fig. S 10). Four NF1d3 target genes with known roles in breast 
cancer progression were examined through QRT-PCR to validate the results from the 
NF1d3 pathway PCR array: interleukin 6 (IL6), intercellular adhesion molecule 1 
(ICAMl), TNFa-induced protein 3 (A2D, TNFAIP3), and chemokine (C-C motif) ligand 
2 (CCL2) (Fig. 15). TNFa increased the expression of IL6, ICAM1, TNFAIP3, and 
CCL2 in both MCF-7 and LCC9 cells (Fig 15A-D). COUP-TFII overexpression reduced 
the basal expression of IL6 and CCL2 in LCC9 cells (Fig. 15A and D) and ICAM1 and 
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TNFAIP3 in both MCF-7 and LCC9 cells (Fig. 15B and C). The TNFa-induction of IL6 
and ICAMI was reduced by COUP-TFIl in LCC9 cells (Fig. 15A and B), while the 
TNFa-induction of TNFAIP3 and CCL2 was reduced in MCF-7 cells (Fig. 15C and D). 
The suppression of IL6, ICAMl, TNFAIP3, and CCL2 expression by COUP-TFII is in 
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Figure 14. COUP-TFII inhibits expression of multiple genes in the NFKB pathway. 
LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 24 h and 
treated with 10 ng/ml TNFa for 6 h before preparing RNA and cDNA. (A) 
SABiosciences NFKB Pathway Array was used to identify genes with expression altered 
greater than 3-fold by addition of COUP-TFII. (B) Heat map displaying fold change of 
individual genes in the array. 
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Figure 15. COUP-TFII inhibits expression of NFKB target genes. 
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 
48 h and treated with 10 ng/ml TNFa for 6 h before preparing RNA and cDNA. mRNA 
expression of NFKB target genes identified in the NFKB pathway array (A. IL6, B. 
ICAM], C. TNFAIP3, D. CCL2) was analyzed by QRT-PCR. Note that relative 
expression of each gene was normalized to pcDNA-transfected, control treated cells 
within each cell line. Values are the mean of 2-7 separate experiments ± SEM. Bars 
indicate p<O.05 between the indicated samples to indicate effect of COUP-TFII on basal 
or TNFa-induced gene expression in each cell line. 
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COUP-TFII suppresses NF!d3 subunit gene expression 
RELB expression was decreased by COUP-TFII overexpression in the NFKB 
pathway PCR array. Increased NFKB subunit expression has been reported in several 
lineages of endocrine-resistant breast cancer cells [87,88,91], but correlation with COUP-
TFII expression has not yet been examined. Consistent with these reports, we observed 
higher NFKB2, REL, and RELB expression in LCC9 versus MCF-7 cells (Fig. 13B). 
TNFa increased the expression of NFKB1, NFKB2, REL, and RELB, but not RELA in 
both MCF-7 and LCC9 cells (Fig. 16A-E). COUP-TFII overexpression inhibited the 
basal expression of REL and RELA in LCC9 cells (Fig. 16C and E). The TNFa-induction 
of NFKB1, REL, and RELB was significantly reduced by COUP-TFII in LCC9 cells (Fig. 
16A, C, and D). At the protein level, COUP-TFII overexpression decreased basal 
NFKB1 p105, NFKB2 plOO, and RelB in MCF-7 cells and NFKB2 plOO in LCC9 cells 
(Fig. 17). COUP-TFII inhibited the TNFa-induced expression of NFKB2 plOO, ReIA, 
RelB, and c-Rel in MCF-7 cells and NFKB1 p105, RelA, and RelB in LCC9 cells (Fig. 
17). Thus, COUP-TFII inhibits TNFa-induced increases in NFKB 1 and RelB at both the 
mRNA and protein levels in LCC9. Differences between protein and mRNA results for 
NFKB subunit expression may have been due to the treatment conditions used for the 
experiment, as NFKB mRNA and protein levels may be altered at different timepoints. 
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Figure 16. COUP-TFII inhibits mRNA expression ofNFKB subunits in LCC9 cells. 
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 
48 h and treated with 10 ng/ml TNFa for 6 h before preparing RNA and cDNA. mRNA 
expression of NFKB subunits (A. NFKB1, B. NFKB2, C. REL, D. RELB, E. RELA) was 
analyzed by QRT-PCR. Bars indicate p<O.05 between the indicated samples to indicate 
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Figure 17. COUP-TFII inhibits protein expression ofNFKB subunits. 
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 
48 h and treated with 10 ng/ml TNFa for 6 h before preparing whole cell extracts. 
Expression of NFKB subunits (NFKBI plOS/pSO, NFKB2 plO~, RelA p6S, RelB, c-Rel) 
was analyzed by western blot with specific antibodies and compared to ~-actin control. 
Note: NFKB2 pS2 was not detectable. 
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COUP-TFII and NFT<!3 expression are inversely correlated in breast cancer patient 
samples 
To examine the relationship between COUP-TFII and NFKB in breast cancer 
patients, publically available microarray gene expression data from 298 ERu+ patients 
treated with tamoxifen for five years was analyzed using the Spearman Rho (pS) statistic 
to determine if there was a correlation between COUP-TFII expression and the 
expression of NFKB subunits and target genes. COUP-TFII (NR2F2) expression was 
inversely correlated with NFKB subunit genes NFKB2 , REL, RELA, and RELB and NFKB 
target genes [CAMl, [L6, and TNFAIP3 (Table 4). In contrast, COUP-TFII (NR2F2) was 
positively correlated with NFKB target gene CCL2 (Table 4). 
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Table 4. Correlation of COUP-TFII expression to NFKB target and subunit gene 
expression in ERa+ breast cancer patients treated with tamoxifen. 
Spearman correlations of gene expression between COUP-TFII (NR2F2) and select 
NFKB-related genes obtained by analysis of micro array data (GSE17705) from 298 
ERa+ breast cancer patients treated with tamoxifen for five years. 
Spearman Correlation to 
Classification Gene Rho p-value COUP-TFII 
NFKB target ICAM1 -0.35 0.0000 Inverse 
IL6 -0.16 0.0063 Inverse 
TNFAIP3 -0.23 0.0000 Inverse 
CCL2 0.14 0.0152 Positive 
NFKB subunit NFKB1 0.08 0.1638 
NFKB2 -0.20 0.0004 Inverse 
REL -0.28 0.0000 Inverse 
RELA -0.34 0.0000 Inverse 
RELB -0.12 0.0428 Inverse 
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COUP-TFII decreases NFKi3-DNA binding 
COUP-TFII can repress gene transcription by direct DNA binding and by direct 
protein:protein interaction with other nuclear receptors and transcription factors 
[108,226]. To determine if COUP-TFII inhibits NFKB-DNA binding, NE from LCC9 
endocrine-resistant cells treated with TNFa to activate NFKB was incubated with 
increasing concentrations of in vitro transcribed/translated COUP-TFII protein and a 
e2PJNFKB RE for an EMSA. In the absence of NE (lane 1), the e2PJNFKB RE did not 
form a retarded band; however, addition of NE from TNFa-treated LCC9 cells formed a 
retarded band (Fig. 18A). The intensity of the NFKB-DNA complex was decreased after 
competition with lOO-fold excess of unlabeled NFKB oligomer (Appendix I, Fig. Sll). 
COUP-TFII alone did not bind to the e2PJNFKB RE oligomer (Fig. 18A); however, the 
amount of NFKB retarded complex was first slightly increased and then decreased with 
the addition of COUP-TFII in increasing concentrations (Fig. 18A). This suggests that 
COUP-TFII directly inhibits NFKB-DNA binding in vitro. A similar effect was seen 
using NE from MCF-7 and LCC9 cells transfected with COUP-TFII. In both MCF-7 
endocrine-sensitive cells and LCC9 endocrine-resistant cells, trans feet ion with COUP-
TFII decreased the amount of e2PJNFKB RE bound complex (Fig. 18B). No increase 
was seen in e2PJNFKB RE-binding with TNFa treatment in either MCF-7 or LCC9 cells 
(Fig. 18B), although induction of NFKB activation with TNFa treatment was detected in 
LCC9 cells under identical treatment conditions (Fig 13A). These data suggest that 
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(A) NE (25 flg) from TNFa-treated (6 h) LCC9 cells was incubated alone or with 
increasing amounts of in vitro transcribed and translated COUP-TFII. e2PJNFKB RE 
DNA probe was added for 1 h prior to EMSA. Values are relative bOlmd e2PJNFKB REI 
total e2PJNFKB RE. (B) 25 flg NE prepared from MCF-7 and LCC9 cells transfected 
with pcDNA3.1 or pcDNA3.1-COUP-TFII for 48 h and treated with TNFa for 6 h was 
incubated with e2PJNFKB RE DNA probe for 1 h to perform EMSA. (A-B) Bottom 
panels contain lighter exposure of unbound e2PJNFKB RE DNA probe. (C) TransAM 
NFKB family assays were performed to measure NFKB subunit activation using 15 flg 
NE from MCF-7 and LCC9 cells transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII 
for 48 h and treated with TNFa for 6 h. Values are the average of two determinations ± 
SEM. * Significantly different p<O.05 from pcDNA-transfected cells. 
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COUP-TFII inhibits RelB, RelA, and p50 NFKB activation 
To examine the effect of COUP-TFII on specific NFKB subunit interaction with 
the NFKB RE, TransAM NFKB family assays were performed (Fig. 18C). RelB activity 
was higher in MCF-7 cells, while NFKB1 p50 activity was greater in LCC9. RelA and c-
ReI activation were not statistically different between the two cell lines. NFKB2 p52 
activation was low in MCF-7 or LCC9 (data not shown), consistent with the lack of p52 
protein expression seen in western blots (Fig. 17). RelB activation was significantly 
decreased by COUP-TFII-transfection in TNFa-treated MCF-7 cells. Activation of RelA 
and p50 was inhibited by COUP-TFII in both MCF-7 and LCC9 TNFa-treated cells as 
well as untreated LCC9 cells. COUP-TFII inhibited NFKB 1/p50 more than RelA. These 
data suggest that COUP-TFII interferes with the binding of NFKB subunits RelB, RelA, 
and p50 to the NFKB RE. 
COUP-TFII interacts with NFKB subunits 
As both COUP-TFII overexpression and in vitro incubation with COUP-TFII 
protein led to decrease in NFKB-DNA binding (Fig. 18A and B), reduced p50 and RelB 
activation (Fig. 18C), and inhibited target gene expression (Fig. 15A-D), co-
immunoprecipitation was used to determine if COUP-TFII interacts with NFKB subunits 
to suppress their activity. Imrnunoprecipitation of COUP-TFII in MCF-7 cells revealed 
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Figure 19. COUP-TFII interacts with NFKB subunits and inhibits coactivator 
function in NFKB activation. 
(A) 500 f.1g NE from MCF-7 cells treated with TNFa for 6 h was immunoprecipitated 
(IP) using a COUP-TFII antibody and separated on a 10% SDS PAGE gel prior to 
transfer to a PVDF membrane. Interaction with NFKB subunits NFKBl p105/p50 and 
RelB was identified using specific antibodies on western blot. (B) LCC9 cells were 
transfected with a NFKB luciferase reporter and pcDNA3.l or pcDNA3.l-COUP-TFII for 
48 h +/- plasmids for the coactivators SRC-l, SRC-2, SRC-3, and CBP. Cells were 
treated with 10 ng/ml TNFa for 6 h before performing dualluciferase assay. Firefly 
luciferase values are shown relative to protein concentration for a representative 
experiment of quadruplicate values ± SEM. * Significantly different P<0.05 from 
pcDNA-transfected cells. Bars connect values which are significantly affected by 
COUP-TFII-transfection vs . coactivator alone. 
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Inhibition of coactivator function by COUP-TFII reduces NFTd3 transcriptional activity 
COUP-TFII has also been reported to reported to inhibit the activity of androgen 
receptor (AR) by competing with coactivators for AR interaction [295]. SRC-1, SRC-2, SRC-
3, and CBP function as coactivators of NFKB-mediated transcription [296]. Each of 
these coactivators also have known interactions with COUP-TFII [226]. To determine if 
COUP-TFII represses NFKB signaling by interfering with coactivator function, LCC9 
cells were cotransfected with a NFKB luciferase reporter with either pcDNA3.1 or 
pcDNA3.1-COUP-TFII plasmids (as in Fig. 13A), and plasmids for SRC-1, SRC-2, 
SRC-3, or CBP. The cells were treated with 10 ng/ml TNFu for 6 hours to activate 
NFKB. SRC-l, SRC-3, and CBP increased NFKB activity in LCC9 cells compared to 
parental vector pcDNA (Fig. 19B). SRC-2 transfection had no effect on NFKB activity. 
Cotransfection with COUP-TFII decreased the activation of NFKB activity by the 
coactivators SRC-1, SRC-3, and CBP (Fig. 19B), implicating COUP-TFII inhibition of 
coactivator function, e.g., competing with NFKB for coactivator interaction, as part of the 
mechanism of NFKB suppression. 
Endocrine-resistant cells are sensitive to NFTd3-inhibition 
Cell proliferation assays were performed to determine phenotypic effects of the 
both the activation of NFKB pathway in endocrine-resistant cells and the suppression of 
NFKB activity by COUP-TFII. MCF-7 and LCC9 cells overexpressing COUP-TFII were 
treated with combinations of TNFu to activate NFKB, 4-0HT to assess endocrine-
sensitivity, and BMS-345541, an NFKB inhibitor that functions by inhibiting IKB kinase 
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and subsequent downstream NFKB activation [297]. BMS-345541 treatment was 
performed with a range of concentrations (0.01-5 J..lM) determined to be effective in 
inhibiting NFKB activity in serum starved MCF-7 and LCC9 cells (Appendix I, Fig. S12). 
The proliferation of MCF-7 cells was largely unaffected by treatment with BMS-345541 
(Fig. 20A). MCF-7 cells displayed reduced viability with 4-0HT or combined 
transfection with COUP-TFII and 4-0HT treatment (Fig. 20A), as previously reported 
[116] and in agreement with MCF-T s phenotype as endocrine-sensitive breast cancer 
cells. Treatment with TNFu did not significantly affect the response of MCF-7 to the 
compounds tested (Fig. 20B). 
When LCC9 cells were treated with increasing concentrations of the NFKB 
inhibitor BMS-345541, a marked reduction in cell proliferation was observed (Fig. 20C), 
reflecting LCC9's increased reliance on a functional NFKB pathway for cell growth as 
endocrine-resistant cells [87,88]. Reduced LCC9 cell viability was observed upon 
combined transfection with COUP-TFII and treatment with 4-0HT, as has been 
previously reported [116]. LCC9 cells transfected/treated with a combination of COUP-
TFII, 4-0HT, and BMS-345541 exhibited a reduction in the higher range of BMS-
345541 concentrations (Fig. 20C). Interestingly, when LCC9 cells were treated with 
TNFu, 4-0HT increased cell proliferation (Fig. 20D). This finding could have important 
translational implications if tamoxifen therapy may cause similar effects in patients with 
high levels of inflammation and NFKB activation. This observed induction of LCC9 cell 
proliferation with TNFu and 4-0HT treatment was blocked by transfection with COUP-
TFII and/or treatment with higher concentrations of BMS-345541 (Fig. 20D). 
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DISCUSSION 
The NFKB pathway is constitutively activated in many types of cancer, including 
breast, gastrointestinal, genitourinary, hematological, and gynecological cancers, through 
a variety of mechanisms [86]. NFKB target genes have roles in oncogenic 
transformation, including apoptosis resistance [292,298], invasion [299], and epithelial to 
mesenchymal transition [300]. Here we demonstrate that COUP-TFII inhibits TNFa-
induced NFKB activity in LCC9 endocrine-resistant breast cancer cells. Consistent with 
previous reports that the NFKB pathway is activated during progression to breast cancer 
endocrine-resistance [87,88,91-93,301], LCC9 cells exhibited greater basal and TNFa-
induced NFKB activity than MCF-7 parental, endocrine-sensitive breast cancer cells. 
This inhibition led to downregulation of TNFa-induced NFKB target gene expression of 
IL6, ICAM], TNFAIP3, and CCL2, which had reduced basal and/or TNFa-induced 
expression upon COUP-TFII overexpression. The inflammatory cytokine IL6 is a 
negative prognostic indicator for breast cancer patients [302], and may have a role in 
trastuzumab resistance [303]. Downregulation of the glycoprotein adhesion molecule 
ICAM1 at the mRNA and protein levels led to a strong suppression of human breast cell 
invasion [304]. The ubiquitin-editing enzyme A20/TNFAIP3 protects MCF-7 cells from 
TNFa-induced apoptosis, and cells overexpressing TNFAIP3 are resistant to tamoxifen 
[292,298,305]. The chemokine ligand CCL2 may play a role in breast cancer 
development and progression, invasion and angiogenesis [299]. 
NFKB subunit expression is regulated by the NFKB pathway in a positive 
feedback loop. Specifically, RelA activates expression of RelB [306] and NFKB2 [307], 
while NFKB l/p50 expression is regulated by a combination of p50 and RelA [308]. 
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Similarly, c-Rel is also capable of autoregulation [309]. Because COUP-TFII suppresses 
genes that are targets of the NFKB pathway, this would also lead to reduced expression of 
the NFKB subunits as observed. Consistent with our data showing higher NFKB subunit 
and target gene expression in LCC9 endocrine-resistant cells, NFKB subunits NFKBl, 
NFKB2, RELA, and REL as well as the NFKB gene targets [CAMl, TNFA[P3, and CCL2 
are also upregulated in inflammatory breast cancer patient samples [310]. A previous 
study showed that overexpression of COUP-TFII inhibited 15d-PGJ2-induced IL-8 
rnRNA expression and promoter activity in U937 human myeloid cells, a result which the 
authors attributed to COUP-TFII competing with PPARy to form a heterodimer with 
RXR or by forming a COUP-TFIIIRXR heterodimer and competing with PPARylRXR 
for DNA binding [311]. 
COUP-TFII was recently identified as one of four NRs that are significant 
predictors of metastasis-free survival in tamoxifen-treated breast cancers, independent of 
ERa expression [85]. We previously observed that COUP-TFII expression was reduced 
with histological grade [115] and this was confirmed in [85]. Here we report for the first 
time that COUP-TFII, i.e., NR2F2 gene expression was inversely correlated with NFKB 
subunit genes NFKB2, REL, RELA, and RELB and NFKB target genes [CAMl, [L6, and 
TNFAIP3 in microarray data from 298 ERa+ breast tumors from patients treated with 
TAM for five years (Table 4). Although COUP-TFII inhibited NFKB target gene CCL2 
in LCC9 cells (Fig. 15), COUP-TFII (NR2F2) was positively correlated with CCL2 in the 
breast tumors (Table 4), indicating potential differences between the patient population 
and cell line responses. This might be due to the effect of the breast tumor 
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microenvironment in the patients, and expression of CCL2 by tumor-associated 
macrophages and other cells [299]. 
Mechanistically, I have demonstrated that COUP-TFII interacts with NFKB 
subunits RelB and NFKBI p105/p50 and inhibits NFKB DNA-binding. COUP-TFII also 
inhibited the ability of coactivators SRC-l, SRC-3, and CBP to enhance NFKB 
activation. The effects of COUP-TFII on NFKB lead to inhibition of cell proliferation, 
with endocrine-resistant LCC9 cell proliferation showing the most reduction when treated 
with an NFKB inhibitor. Overall, these data indicate a general downregulation of NFKB 
target gene expression by COUP-TFII, which could have important phenotypic 
consequences on endocrine sensitivity. As NFKB is highly activated in endocrine-
resistant cells, blockage of downstream target gene expression by COUP-TFII may be a 
mechanism by which COUP-TFII enables breast cancer cells to maintain endocrine 
sensitivity. Natural product inhibitors of NFKB activity such as parthenolide [88], 
curcumin [312,313], and ellagic acid [314] , as well as synthetic inhibitors [89,297] 
provide compounds for both experimental and future translational purposes. These data 
point to potential for the combination of NFKB inhibitors with antiestrogen therapies, e.g. 
tamoxifen, to promote endocrine sensitivity, as well as the availability of COUP-TFII as 
a marker for response. 
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CHAPTER V - IDENTIFICATION OF COUP-TFII-INTERACTING PROTEINS 
IN TAMOXIFEN-TREATED BREAST CANCER CELLS 
INTRODUCTION 
COUP-TFIl is an orphan nuclear receptor that may play multiple roles in 
endocrine resistance. COUP-TFII expression is reduced in endocrine-resistant breast 
cancer cell lines, and overexpression of COUP-TFII restores endocrine sensitivity [116]. 
Part of the mechanism of maintenance of endocrine sensitivity by COUP-TFII involves 
its ability to suppress activation of NFKB pathway, as described in Chapter IV. As 
detailed in Chapter II, many pathways have been reported to be amplified in endocrine 
resistance and play important roles as both prognostic indicators and areas for potential 
therapeutic intervention, such as COUP-TFIL As outlined in previous chapters, the role 
of COUP-TFII in multiple pathways involved in cell differentiation, apoptotic resistance, 
migration, invasion, and others seems to be dependent on cellular context and interacting 
partners [226]. 
Mass spectrometry-based analyses to identify protein interactions can yield 
important information about disease states [315]. Protein interaction networks provide 
detailed pathways to enhance understanding of a protein in a particular cellular context 
[316]. Analyzing the roles of proteins within a particular protein complex or network 
produces valuable information about the specific activities of the proteins within the cell 
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[317]. Proteomics is especially useful when studying drug resistance, resulting in 
additional angles from which to target a particular pathway [317]. As described in 
Chapter III, a previous study to identify COUP-TFII-interacting proteins in MCF-7 cells 
identified nucleolin as a coactivator for COUP-TFII-mediated transcription of retinoic 
acid receptor B2 (RARB2) [115]. 
The focus of the present study was to identify proteins that interact with COUP-
TFII in ethanol- versus tamoxifen-treated MCF-7 cells to define interacting proteins 
changed by treatment with tamoxifen. The goal of this study was to better understand the 
function of COUP-TFII in maintenance of breast cancer cellular response to tamoxifen 
treatment and how loss of COUP-TFII expression confers endocrine resistance to breast 
cancer cells. Heat shock protein 27 (HSP27) was identified amongst the proteins 
interacting with COUP-TFII more strongly in tamoxifen-treated cells. Given conflicting 
reports linking HSP27 to both increased and decreased drug resistance [318-325], HSP27 
was selected for additional studies. 
HSP27 interaction with COUP-TFII was confirmed in MCF-7 breast cancer cells 
by co-immunoprecipitation experiments. Regulation of HSP27 expression by estradiol 
and tamoxifen was investigated, as well as the expression and phosphorylation of HSP27 
in both endocrine-resistant and trastuzumab-resistant breast cancer cells. Further studies 
are necessary to fully determine the relationship between HSP27 and COUP-TFII. 
MATERIALS AND METHODS 
Chemicals and antibodies 
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4-hydroxytamoxifen (4-0HT) and 17~-estradiol (E2) were purchased from Sigma-
Aldrich (St. Louis, MO). The following antibodies were purchased: polyclonal COUP-
TFII (Abcam, Cambridge, MA); monoclonal (rnAB) anti-human COUP-TFII (R&D 
systems, Minneapolis, MN; PP-H7147-00); mAB anti-FLAG M2 and ~-actin (Sigma-
Aldrich); mAB HSP27 (Santa Cruz, Santa Cruz, CA), polyclonal phospho-HSP27 
(Ser82) and mAB HER2 (c-ErbB2/c-Neu, Millipore, Billerica, MA), HRP-conjugated 
secondary antibodies were from GE Healthcare (Piscataway, NJ). 
Cell culture 
MCF-7 breast cancer cells were purchased from A TCC and used at passage < 10. 
Endocrine-resistant LCC2 [326], LCC9 [285], and L Y2 [327] breast cancer cells were 
obtained from Robert Clarke (Georgetown University). MCF-7, LCC2, LCC9, and LY2 
cells were maintained in improved MEM (IMEM) (Cellgro, Manassas, VA) 
supplemented with 5% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, 
GA) and 1 % penicillin/streptomycin (PIS, Cellgro). JIMT-l trastuzumab-resistant breast 
cancer cells [328] were obtained from Gail Sonenshein (Tufts University) and maintained 
in DMEM (Cellgro) supplemented with 10% FBS and 1 % PIS. All cells were maintained 
in a 37°C incubator containing 5% CO2. 
Immunoprecipitation of CO UP- TFII-FLAG-interacting proteins 
MCF-7 cells were transfected with pIRES-COUP-TFII-FLAG for 24 h using 
FuGENE HD (Roche, Indianapolis, IN) according to manufacturer's instructions. Cells 
were 'serum-starved' using phenol red-free IMEM supplemented with 5% dextran-coated 
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charcoal-stripped serum (Atlanta Biologicals) for 24 h before being treated with 100 nM 
4-0HT or vehicle control EtOH for 2 h. One mg of whole cell extract (WCE) prepared in 
lysis buffer (10% glycerol, 50 rnM HEPES pH 8.0, 100 mM KCI, 2 rnM EDTA, 0.1% 
NP-40, 2 rnM DTT, protease inhibitor cocktail (Roche), 10 mM NaF, and 0.25 rnM 
NaV04) [329] was incubated with EZview™ Red ANTI-FLAG® M2 Affinity gel 
(Sigma-Aldrich) for 4 h at 4°C with constant rotation. Washes and elution was 
performed in spin chromatography columns (BioRad, Hercules, CA). COUP-TFII-
FLAG-interacting proteins were eluted by incubation with 100 III 6M urea + 100rnM 
(N~)HC03 for 30 min with constant rotation. Three elution volumes were subsequently 
pooled for further analysis. 
Identification of CO UP-TFII-interacting proteins by 2D-LC-MSIMS 
COUP-TFII-FLAG protein complexes were analyzed with a Thermo LTQ linear 
ion trap using a previously described 2D-LC-MSIMS approach [329]. Database 
searching was performed with tandem mass spectra extracted by ReadW and converted to 
mzXML format. Charge state deconvolution and deisotoping were not performed. All 
MSIMS samples were analyzed using SequestSorcerer (Sage-N, Milpitas, CA). Sequest 
was set up to search a FASTA-formatted human protein database (Human Ref Seq, 2007). 
Searches were performed with a fragment ion mass tolerance of 1.00 Da and a parent ion 
tolerance of 1.2 Da. Iodoacetamide derivative of cysteine was specified as a fixed 
modification. Oxidation of methionine was specified as a variable modification. 
Scaffold (version Scaffold 3.0.00, Proteome Software Inc., Portland, OR) was 
used to validate MSIMS based peptide and protein identifications. Protein probabilities 
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were assigned by the Protein Prophet algorithm [330]. Protein identifications were 
accepted if they could be established at greater than 95.0% probability. Proteins that 
contained similar peptides but could not be differentiated based on MSIMS analysis alone 
were grouped to satisfy the principles of parsimony. 
Co-immunoprecipitation (co-IP) and immunoblotting 
Nuclear and cytosolic proteins were prepared as in Chapter III [115]. 4!J.g 
COUP-TFII polyclonal antibody (Abcam) or rabbit IgG (Invitrogen, Carlsbad, CA) were 
added to 50 !J.I Dynabeads Protein A (Invitrogen) in PBS (Cellgro) for 20 min at 4°C. 
400 !J.g NE was added and incubated for 4 h at 4°C with rotation. Beads were washed 3x 
with PBS and bound proteins were eluted by incubation with Elution Buffer (Invitrogen). 
Proteins were separated by SDS-PAGE and analyzed by western blot [115,116]. 
Cell treatment 
Cells were 'semm-starved' for 48 h pnor to treatment with ethanol (EtOH, 
vehicle control), 10 nM E2, or 100 nM 4-0HT for 6 h, as indicated. 
RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR) 
RNA isolation, cDNA preparation, and QRT-PCR were performed as in [115]. 
QRT-PCR for HSP27 (HSPBl) and 18S, used Taqman Gene Expression Assays 
(Invitrogen). COUP-TFII (NR2F2) and GAPDH were measured using the SYBR green 
method as in [116]. All QRT-PCR was performed in the ViiA 7 Real-Time PCR system 
106 
(Applied Biosystems, LifeTechnologies). Fold change was calculated from the ~~CT 
values with the formula 2-~~CT and data are relative to EtOH-treated cells. 
Statistical analysis 
Values are reported as ± SEM. Student's t test was used for comparisons between 
control and treatment. P values considered statistically significant are indicated. 
RESULTS 
Identification of CO UP-TFII-associated proteins in ethanol- and tamoxifen-treated cells 
To identify COUP-TFII-interacting proteins which are increased in their 
association with COUP-TFII either in EtOH (vehicle control) or 4-0HT treated MCF-7 
cells, 2D-LC-MSIMS was performed following immunoprecipitation of COUP-TFII-
FLAG and interacting proteins from EtOH and 4-0HT-treated MCF-7 cells. Efficiency 
of FLAG affinity purification is demonstrated in Figure 21. The majority of COUP-TFII-
FLAG was bound by the FLAG affinity gel and not lost in flow through or washes 
(Figure 21A). COUP-TFII-FLAG was detected by western blot in both EtOH and 4-
OHT-treated cells and not in vector control-transfected cells (Figure 21B). From the 
mass spectrometry analysis, proteins were identified as interacting with COUP-TFII 
specifically in EtOH or 4-0HT-treated cells, as well as a group of proteins which were 
found in both EtOH and 4-0HT treated samples to varying degrees (Table 5). While 
three independent IP-mass spectrometry experiments were performed, COUP-TFII was 
not identified in the second experiment, and data from this experiment were not included 
in the summary of proteins identified as interacting with COUP-TFII. COUP-TFII-
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interacting proteins (from experiments 1 and 3) were subsequently categorically assigned 
as enriched in the ethanol or tamoxifen-treated groups, or equal/indistinguishable 
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Figure 21. Efficiency of COUP-TFII-FLAG purification by FLAG affinity gel. 
A, 20 Jlg WCE from MCF-7 cells transfected with COUP-TFII-FLAG (input), 25 Jll flow 
through from incubation of WCE with FLAG affinity gel, 25 Jll IF washes , and 10 Jll of 
elutions 1 and 2 (10% of elution volume) were analyzed by western blot to detect the 
presence of COUP-TFII-FLAG. B, 20 Jlg WCE from empty vector pIRES or COUP-
TFII-FLAG-transfected cells treated with EtOH or 4-0HT (input) or 10 Jll of pooled 
elutions 1-3 were analyzed by western blot to detect the presence of COUP-TFII-FLAG 
before and after immunoprecipitation. 
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Table 5. COUP-TFII-interacting proteins in ethanol- and tamoxifen-treated MCF-7 
cells. 
COUP-TFII-FLAG-transfected MCF-7 cells were treated with EtOH (Et) or 100 nM 4-
OHT (T) for 2 h. 1 mg WCE was incubated with anti-FLAG affinity gel. COUP-TFII-
FLAG and interacting proteins were eluted with 6 M urea and 100 mM (NH4)HC03. 2D-
LC-MS/MS was used to identify proteins. The number of assigned spectra for identified 
proteins (Values) was normalized to number of spectra for COUP-TFII (bottom row in 
this Table) in each experiment. Qualitative assignment to ethanol, tamoxifen, and equal-
interacting groups was made based on normalized values. 
Experiment 1 Experiment 2 
Values Normalized Values Normalized 
MW Qualitative 
Identified Proteins (kOa) Et T Et T Et T Et T enrichment 
myosin-9 (MYH9) 227 102 24 3.00 0.67 10 4 3.33 4.00 Ethanol 
spectrin alpha chain 
(SPTAN1) 285 4 2 0.12 0.06 11 2 3.67 2.00 Ethanol 
Calmodulin (CALM) 17 10 0.29 7 2 2.33 2.00 Ethanol 
spectrin beta chain 
(SPTBN1) 275 4 0 0.12 4 1.33 Ethanol 
tubulin alpha-1 B chain 
(TUBA1B) 50 41 50 1.21 1.39 6 10 2.00 10.00 Tamoxifen 
RNA-binding protein 
FUS (FUS) 53 25 26 0.74 0.72 6 2.00 Tamoxifen 
serum albumin 
preproprotein (ALB) 69 10 8 0.29 0.22 2 2 0.67 2.00 Tamoxifen 
heterogeneous nuclear 
ribonucleoprotein U 
(HNRNPU) 89 9 10 0.26 0.28 2 2 0.67 2.00 Tamoxifen 
keratin, type I 
cytoskeletal 10 (KRT10) 59 65 59 1.91 1.64 2 2 0.67 2.00 Tamoxifen 
60S acidic ribosomal 
protein P1 (RPLP1) 12 4 5 0.12 0.14 2 2 0.67 2.00 Tamoxifen 
probable A TP-
dependent RNA 
helicase DDX5 (DDX5) 69 28 27 0.82 0.75 2 2 0.67 2.00 Tamoxifen 
homeobox prox 1 
(PROX1) 28 14 16 0.41 0.44 2 2 0.67 2.00 Tamoxifen 
heat shock cognate 71 
kDa protein (HSPA8) 71 48 53 1.41 1.47 2 4 0.67 4.00 Tamoxifen 
78 kDa glucose-
regulated protein 
precursor (HSPA5) 72 23 30 0.68 0.83 2 2 0.67 2.00 Tamoxifen 
heat shock protein beta-
1 (HSPB1) 23 10 14 0.29 0.39 2 2.00 Tamoxifen 
F-actin-capping protein 
subunit alpha-1 
(CAPZA1) 33 6 3 0.18 0.08 2 2.00 Tamoxifen 
histone H4 (HIST1 H4) 11 34 27 1.00 0.75 8 4 2.67 4.00 Equal 
filamin-A (FLNA) 280 35 40 1.03 1.11 8 2 2.67 2.00 Equal 
myosin-14 (MYH14) 228 7 0.21 4 2 1.33 2.00 Equal 
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keratin, type II 
cytoskeletal 8 (KRT8) 54 77 93 2.26 2.58 5 2 1.67 2.00 Equal 
myosin-Ib (MY01 B) 125 8 1 0.24 0.03 4 2 1.33 2.00 Equal 
keratin , type I 
cytoskeletal 9 (KRT9) 62 63 38 1.85 1.06 2 2 0.67 2.00 Equal 
2,4-dienoyl-CoA 
reductase, mitochondrial 
precursor (DECR1) 36 6 6 0.18 0.17 3 1 1.00 1.00 Equal 
keratin, type II 
cytoskeletal 1 (KRT1) 66 53 47 1.56 1.31 0.33 Equal 
myosin-Ic (MY01 C) 122 4 0.12 3 1.00 Equal 
X-ray repair cross-
complementing protein 6 
(XRCC6) 70 59 56 1.74 1.56 3 1.00 Equal 
plasminogen activator 
inhibitor 1 RNA-binding 
protein (SERBP1) 45 21 21 0.62 0.58 1.00 Equal 
COUP transcription 
factor 2 (NR2F2) 46 34 36 1.00 1.00 3 1.00 1.00 
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Functional Annotation Clustering of CO UP- TFII-interacting proteins 
The Database for Annotation, Visualization, and Integrated Discovery (DAVID, 
version 6.7) [331,332] was used to identify functionally related groups amongst the 
identified COUP-TFII-interacting proteins in the ethanol, tamoxifen, and equally 
enriched groups (Table 6). This bioinformatic analysis allows for detection of biological 
themes amongst groups of proteins to identify pathways that may be relevant in a 
particular state [331,332]. Gene lists compiled from Table 5 were entered into the 
DA VID database and functional annotation clustering was performed using high 
stringency for analysis. Repeated terms were removed from the resulting list (Table 6). 
Common themes amongst the groups were calmodulin-binding (ethanol and 
equal) and RNA splicing/alternative splicing (ethanol and tamoxifen) (Table 6), 
suggesting these may have importance to COUP-TFII. As calmodulin was identified 
amongst the COUP-TFII-interacting proteins (Table 6), this may indicate that this 
interaction has significance. A role for COUP-TFII in RNA splicing has not yet been 
reported, and this may also be a new area for study given potential interactions with 
DEAD box protein 5 (DDX5), RNA-binding protein PUS (PUS), and heterogeneous 
nuclear ribonucleoprotein U (HNRNPU) with tamoxifen treatment (Table 5 and 6). 
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Table 6. Functional Annotation Clustering ofCOUP-TFll-interacting proteins. 
Proteins identified as enriched in the EtOH or tamoxifen-treated samples or proteins 
identified as interacting with COUP-TFII relatively the same with either treatment were 
entered into the DAVID database to identify biological relationships between the 
proteins. 
Fold 
Term Count p-value Enrichment Bonferroni 
ETHANOL 
Cluster 1: MYH9, SPTAN1, SPTBNl 
Cortical cytoskeleton 3 4.3E-05 195.64 0.003 
Calmodulin-binding 3 1.2E-04 120.22 0.004 
Cell cortex 3 1.2E-04 115.50 0.008 
Actin-binding 3 4.9E-04 58.41 0.018 
Plasma membrane part 3 7.9E-02 4.35 0.996 
Alternative splicing 3 3.4E-Ol 1.93 1.000 
Cluster 2: MYH9, SPTAN1, CALM, SPTBN1 
Cytoskeletal protein binding 4 5.8E-05 25.76 0.002 
Acetylation 4 2.6E-03 7.30 0.091 
Non-membrane-bounded organelle 4 8.4E-03 4.92 0.435 
Plasma membrane 4 2.6E-02 3.38 0.831 
Phosphoprotein 4 5.4E-02 2.65 0.871 
Polymorphism 4 2.2E-Ol 1.67 1.000 
TAMOXIFEN 
Cluster 1: DDXS, FUS, HNRNPU 
RNA splicing 3 0.018 12.99 0.918 
Cluster 2: DDXS, HSPA8, HNRNPU, TUBAIB, 
HSPAS 
Nucleotide-binding 5 0.012 4.75 0.568 
Cluster 3: ALB, HSPB1, HSPAS 
Negative regulation of apoptosis 3 0.027 10.42 0.978 
Cluster 4: ALB, HSPA8, HSPAS 
Cytoplasmic membrane-bounded vesicle 3 0.079 5.81 0.997 
Cluster 5: DDXS, HSPA8, HNRNPU, HSPAS 
ATP-binding 4 0.036 4.84 0.923 
Cluster 6: ALB, FUS, HSPAS 
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Metal ion binding 3 0.910 0.78 1.000 
EQUAL 
Cluster 1: MY01B, MY01C, MY014 
Myosin 3 3.1E-04 102.86 0.019 
Calmodulin-binding region 3 9.5E-04 57.44 0.026 
Cluster 2: MYOIB, MY01C, MY014, FLNA 
Actin-bind ing 4 2.3E-04 28.32 0.015 
Cytoskeletal protein binding 4 5.7E-03 9.37 0.310 
Cluster 3: KRTl, KRT8, KRT9 
Intermediate filament 3 7.2E-04 67 .26 0.044 
Cytoskeletal keratin 3 1.8E-03 40.42 0.013 
Structural molecule activity 3 8.3E-02 5.58 0.996 
Cluster 4: MYOIB, MY01C, MY014, XRCC6 
ATP-binding 4 2.7E-02 5.27 0 .824 
Nucleotide-binding 4 5.1E-02 4.15 0.962 
Cluster 5: XRCC6, HISTlH4, MY01C 
Nucleoplasm 3 1.5E-01 3.95 1.000 
Intracellular organelle lumen 3 4.2E-01 1.96 1.000 
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Endogenous nuclear interaction of COUP-TFlI with HSP27 
Heat shock protein beta-l (HSPBl), also known as heat shock protein 27 
(HSP27), is a member of the small heat shock protein family of chaperones that are 
involved in maintenance of protein stability and prevention of abnormal protein folding 
or aggregation [333,334]. HSP27 is increased expression in breast carcinoma and other 
cancers and can inhibit caspase-dependent apoptosis [335-337]. HSP27 expression has 
been reported to be increased by chemotherapy in breast cancer patients and to be 
correlated with reduced disease free survival [318]. HSP27 is known to interact with 
ER~ [338], ERa, progesterone receptor (PR), and androgen receptor (AR) [339]. Based 
on these reports, HSP27 was selected from the list of proteins identified to interact with 
COUP-TFII, and enriched in cells treated with 4-0HT, for further investigation. 
Endogenous COUP-TFII-HSP27 interaction was examined in MCF-7 cells. 
HSP27 is abundantly present in both the NE and CE of MCF-7 cells, while COUP-TFII is 
only present in the NE (Fig. 22A). HSP27 was detected via western blot following IP of 
NE with a polyclonal COUP-TFII antibody (Fig. 22A). No HSP27 was present in the 
negative control IgG or antibody-only lanes (Fig. 22A). Interaction of COUP-TFII with 
calmodulin, another protein identified by mass spectrometry to interact with COUP-TFII, 
although enriched when cells were treated with EtOH (Table 5), was also verified 
through IP (Fig. 22A). 
To examine whether COUP-TFII-HSP27 interaction was altered following 
treatment with 4-0HT, a similar IP was performed using NE prepared from MCF-7 cells 
treated with EtOH (vehicle control) or 4-0HT for 2 h (Fig. 22B). No significant change 
in COUP-TFII-HSP27 interaction was observed following treatment with 4-0HT as 
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compared to EtOH (Fig. 22B). COUP-TFII and HSP27 expression and subcellular 
localization were also not affected by treatment (Fig. 22B). COUP-TFII interaction with 
calmodulin was also verified via IP in MCF-7 cells (Fig. 22A), although follow-up 
experiments to elucidate the function of this interaction have not yet been performed. 
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Figure 22. Endogenous nuclear interaction of COUP-TFII with HSP27 and 






400 ).1g NE from MCF-7 cells was immunoprecipitated with polyclonal COUP-TFII 
antibody or negative control rabbit IgG (negative control) and analyzed by western blot 
for COUP-TFII and interacting proteins identified via mass spectrometry. 40).1g NE or 
CE was used as input control. A, COUP-TFII interacts with HSP27 and calmodulin in 
MCF-7 cells. B, COUP-TFII interacts with HSP27 in EtOH and 4-0HT -treated MCF-7 
cells. 
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Regulation of HSP27 by estradiol and tamoxifen in endocrine-resistant breast cancer 
cells 
The promoter region of HSP27 contains a Spl and half ERE site reported to be 
responsible for the upregulation of HSP27 expression by E2 through a SpllER complex 
[340]. To examine both the relative expression of HSP27 in breast cancer cell lines with 
increasing endocrine resistance, as well as the effect of E2 and 4-0HT treatment on 
HSP27 expression, MCF-7, LCCl, LCC2, LCC9, and LY2 cells were treated with 10 nM 
E2, 100 nM 4-0HT, or EtOH (vehicle control) for 6 h. Increased HSP27 expression was 
observed in LCCl estrogen-independent but tamoxifen-sensitive cells [326] as compared 
to MCF-7 estrogen-dependent, tamoxifen-sensitive cells. LCC2 cells, which are both 
estrogen-independent and tamoxifen-resistant [326], had reduced HSP27 expression 
compared to MCF-7. LCC9, estrogen-independent, tamoxifen and fulvestrant-resistant 
cells [285], displayed a further reduction in HSP27 expression. LY2, a breast cancer cell 
line that is resistant to tamoxifen, fulvestrant, and LY1170l8 (a raloxifene analog) [327] 
and has lmdergone epithelial to mesenchymal transition, had undetectable expression of 
HSP27 by QRT-PCR. 
Previous reports have indicated regulation of HSP27 by estrogen signaling [340]; 
however, this was not confirmed in these experiments. E2 treatment had no statistically 
significant effect on HSP27 expression in any of the cell lines examined (Fig. 23), 
reflecting potential differences the breast cancer cell lines used by investigators, the 
methods of detection, altered endocrine responses of the tamoxifen-resistant cell lines, 
etc. 4-0HT treatment in LCCl cells lead to a slight increase in HSP27 expression (Fig. 
23)" while no effect was observed in other cell lines. Increased HSP27 expression in 
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response to 4-0HT treatment would be consistent with reports that cellular stress and 
drug treatment induce HSP27 expression [336,341]. 
HSP27 and COUP-TFII expression is reduced in endocrine-resistant and trastuzumab-
resistant breast cancer cells 
To follow up on the observed differences in steady state mRNA expression of 
HSPBl (Fig. 23), HSP27 expression was also analyzed by western blot of WCE from 
endocrine-sensitive MCF-7 cells and endocrine-resistant LCC2, LCC9, and LY2 cells. 
As seen at the mRNA level (Fig. 23), a reduction in HSP27 expression was prominent in 
L Y2 cells (Fig. 24A). LCC2 and LCC9 cells displayed HSP27 expression approximately 
equivalent to MCF-7 cells. Interestingly, the lower molecular weight band of HSP27 
seen in MCF-7, LCC2, and LCC9 was absent in L Y2 cells (Fig. 24A). HSP27 expression 
was also examined in a trastuzumab-resistant breast cancer cell line, JIMT-l (Fig. 24B). 
Trastuzumab (Herceptin) is a monoclonal antibody used for the treatment of HER2+ 
breast cancer patients [12]. JIMT -1 cells display clinical resistance to trastuzumab, as 
they were derived from a pleural effusion of a patient whose disease had progressed to 
trastuzumab-resistance [328]. Similar to LY2 cells, HSP27 expression was reduced in 
JIMT-l cells, and the lower band seen in MCF-7 cells was not present (Fig. 24B). 
Phosphorylation of HSP27 by MAPK at serine 15, 78, and 82 has also been 
shown to be important to its cellular function and localization [319,325]. Cell stress, 
such as heat shock, chemotherapy, or cytokine exposure, can induce phosphorylation of 
HSP27 [337]. Phosphorylation of HSP27 at Ser82 was also examined in the same cell 
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lines, and the pattern of p-Ser82-HSP27 was found to mirror the expression of HSP27 in 
all 5 cell lines examined (Fig. 24A and B). 
To investigate a possible correlation between HSP27 and COUP-TFII expression, 
COUP-TFII expression was also analyzed by western blot. As previously reported [116], 
COUP-TFII expression is reduced in the endocrine-resistant LCC2, LCC9, and LY2 cells 
as compared to MCF-7 (Fig. 24A). COUP-TFII expression was also much lower in 
JIMT -1 cells compared to MCF-7 endocrine-sensitive cells, suggesting a potential role 
for COUP-TFII in trastuzumab-resistance (Fig. 24B). 
COUP-TFIIIHSP27 and HER2 expression are inversely correlated 
We have previously reported an inverse correlation between COUP-TFII and 
HER2 expression in tamoxifen-treated patient tumors via immunohistochemistry [115]. 
To determine if COUP-TFII and HSP27 expression are correlated to HER2 expression in 
the endocrine-resistant and trastuzumab-resistant cell lines, a western blot was performed 
using a HER2 antibody. HER2 expression was undetectable in MCF-7 and LCC2 cells 
(Fig. 24A). Very low expression of HER2 was detected in LCC9 cells, while L Y2 cells 
had the greatest HER2 expression of the endocrine-resistant cell lines (Fig. 24A). JIMT-
1 cells are trastuzumab-resistant and, as part of their identified phenotype, have been 
reported to have increased expression of HER2 [328]. JIMT -1 cells had the highest 
HER2 expression detected in any of the cell lines examined (Fig. 24B). These data 
suggest a trend towards an inverse pattern of expression between COUP-TFIIIHSP27 and 
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Figure 23. Regulation of HSP27 expression by E2 and 4-0HT in TAMS and T AMR 
cells. 
QRT-PCR for HSPBl (HSP27) in MCF-7, LCC1, LCC2, LCC9, and L Y2 cells treated 
with EtOH, 10 nM E2, or 100 nM 4-0HT for 6 h. Each bar is the average of triplicate 




















Figure 24. Expression of HSP27, HER2, and COUP-TFII in endocrine-resistant and 
trastuzumab-resistant cells. 
Western blot ofWCE (40 /-lg) from (A) TAMS MCF-7 and TAMR LCC2, LCC9, and 
L Y2 breast cancer cells or (B) MCF-7 and trastuzumab-resistant JIMT -1 breast cancer 
cells to evaluate the expression of HER2, phospho-HSP27 (Ser82), HSP27, and COUP-
TFII relative to ~-actin. 
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DISCUSSION 
The role of HSP27 in breast cancer response to antiestrogens and other treatments 
has been controversial. Examination of HSP27 expression by immunohistochemistry in 
ERu+ tamoxifen-treated breast cancer patients with metastatic disease revealed no 
statistically significant association between HSP27 and response to tamoxifen therapy 
[320]. This is in contrast to an early study which reported that patients with HSP27+ 
tumors responded better to tamoxifen and had a lower failure rate than patients with 
HSP27- tumors, implicating loss of HSP27 in progression to tamoxifen-resistance [321]. 
Another group reported increased resistance to doxorubicin in MDA-MB-231 cells 
overexpressing HSP27 [342]. However, HSP27 expression was reduced in doxorubicin-
resistant MCF-7/adr cells. This was also correlated to reduced heat shock factor 1 
expression and increased NFKB p65 and mutant p53 expression in the MCF-7/adr cells 
[324]. A trastuzumab-resistant cell line, SKBR3 HR, expresses increased levels of 
HSP27 compared to the parental SKBR3 cell line. Knockdown of HSP27 expression 
resulted in increased trastuzumab sensitivity, although no correlation between HSP27 and 
trastuzumab sensitivity could be established across a panel of cell lines [322]. Further 
evaluation of the reduced HSP27 expression in endocrine-resistant and trastuzumab-
resistant breast cancer cells (Fig. 24A and B) and the interaction of HSP27 with COUP-
TFII (Fig. 22A and B) identified herein may provide more clues. Evaluation of the 
specific identity of the lower molecular weight band of HSP27 present in MCF-7, LCC2, 
and LCC9 but not LY2 and JIMT -1 cells (Fig. 24A and B) may also be of interest. 
The phosphorylation status of HSP27 may also contribute to its ability to 
modulate chemoresistance [322,323]. Decreased phosphorylation of HSP27 at Ser82 
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with increasing endocrine resistance or trastuzumab resistance corresponding to 
decreased HSP27 expression was identified in this study (Fig. 24A-B), but 
phosphorylation of other sites may also be important. Phosphorylation of HSP27 at 
Ser78 is regulated downstream of the HER2-p38 MAPK pathway [343], and may also 
play a role in trastuzumab sensitivity. Induction of apoptosis was associated with 
increased phosphorylation of HSP27 in response to TNFa or 4-0HT treatment, 
suggesting HSP27 phosphorylation may play a role in treatment response [325]. 
Phosphorylation of HSP27 also increases its nuclear translocation, while 
unphosphorylated HSP27 remams distributed throughout the cell [319]. It would be 
interesting to see if phosphorylation plays a role in HSP27 interaction with COUP-TFII. 
Much remains to be determined about the role of phosphorylation in HSP27 function and 
effect on drug sensitivity. Further investigation into whether phosphorylation of HSP27 
is tumor-promoting or tumor-suppressive will yield insight into the complex cellular 
actions of HSP27. 
In addition to HSP27, other cancer-associated proteins were found to interact with 
COUP-TFII through this proteomic study, which will require further investigation. The 
interaction between COUP-TFII and calmodulin was also verified herein (Fig. 22A). 
Calmodulin, a calcium binding protein, also interacts with EGFR [344], HER2 [345], 
ER~ [346], and ERa [347,348]. Binding of calmodulin to ERa stabilizes ERa [349], and 
tamoxifen inhibits the interaction of ERa and calmodulin [350]. Calmodulin appears to 
play a role in HER2 stimulated SKBR3 cell proliferation since calmodulin inhibition 
decreased HER2-stimulated cell growth [345]. Further investigation of the function of 
the interaction between COUP-TFII and calmodulin would be of interest. Also found to 
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interact with COUP-TFII was DEAD box protein 5 (DDX5), which interacts with ERa 
where it functions as a transcriptional coactivator [351]. DDX5 also interacts with other 
ERa and COUP-TFII coactivators SRC-1, SRC-2, and SRC-3 [352]. Interaction between 
DDX5 and COUP-TFII has not yet been reported, but would be another potential area to 
pursue. 
In conclusion, novel COUP-TFII-interacting proteins have been identified 
through a proteomic screen and their relative interaction with COUP-TFII following 
treatment with EtOH or 4-0HT has been qualitatively analyzed. COUP-TFII-HSP27 
interaction in MCF-7 cells and reduced expression of HSP27 in endocrine-resistance and 
trastuzumab-resistance raises many questions about the function of these proteins in 
breast cancer cells. Of particular interest will be analyses of HSP27 localization and 
phosphorylation in endocrine-resistant and trastuzumab-resistant cells, and the effect of 
COUP-TFII on these properties. 
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CHAPTER VI - RESEARCH IMPLICATIONS 
Breast cancer is the most common type of cancer diagnosed in women and the 
second leading cause of female cancer death [4]. The use of antiestrogen therapy such as 
selective estrogen receptor modulators (SERMs) greatly increases survival, with five 
years of tamoxifen therapy reducing mortality rate by 32% and recurrence rate by 45% 
[50]. Despite the initial efficacy of this treatment, approximately 40% of patients 
undergoing antiestrogen therapy progress to metastatic disease and die [56]. 
Identification of novel treatment combinations, biomarkers, and drug targets is of great 
importance in increasing the effectiveness of antiestrogen therapy for patients. In this 
study, I have described the function of the orphan nuclear receptor COUP-TFII in breast 
cancer and endocrine resistance. 
COUP-TFII-interacting proteins in MCF-7 breast cancer cells were identified in 
studies described in Chapter III. The interaction between COUP-TFII and nucleolin was 
verified through co-immunoprecipitation and an in vitro binding assay [115]. Nucleolin 
is a multifunctional protein that has roles in mRNA stability, ribosome biogenesis, 
apoptosis, and the modulation of gene expression as a coregulator [253-257]. As COUP-
TFII transcriptional action is largely modified by interaction with coregulators [226], a 
role for nucleolin as a coregulator for transcription of a COUP-TFII-regulated gene 
retinoic acid receptor B2 (RARB2) was explored. Nucleolin enhanced COUP-TFII 
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activated RARB2 expressIOn, and siRNA-mediated knockdown of COUP-TFII or 
nuc1eolin reduced RARB2 expression [115]. This indicates that both COUP-TFII and 
nuc1eolin are necessary for the basal expression of RARB2. Binding of COUP-TFII to 
the promoter of RARB2 was also verified, as well as COUP-TFII regulation of a 
RARB2-target gene, retinoid receptor-induced gene-1 (RRIG1) [115]. Supporting 
evidence for the importance of COUP-TFII in breast cancer was provided by 
immunohistochemical (rnC) staining of breast cancer tumor tissue microarrays, 
where an inverse correlation was found between COUP-TFII expression and tumor 
grade. COUP-TFII and nuc1eolin expression were also positively correlated in ERa+ 
invasive ductal carcinomas [115]. These data enhance our understanding of the 
regulation of COUP-TFII' s transcriptional activity, as well as the characteristics of 
COUP-TFII expression in breast cancer tissue. 
Several reports have implicated increased NFKB activity as a driving pathway 
in endocrine-resistance breast cancer [87,88,280-284]. As COUP-TFII expression is 
reduced in endocrine-resistant breast cancer, and COUP-TFII can repress the activity 
of other transcription factors, Chapter IV explores a role for COUP-TFII in 
suppression of NFKB activity in breast cancer. Endocrine-resistant LCC9 cells 
displayed much greater basal and TNFa-induced NFKB activity than endocrine-
sensitive MCF-7 cells. Transfection of COUP-TFII in endocrine-resistant LCC9 cells 
reduced NFKB activation. COUP-TFII suppressed both the basal and TNFa-induced 
expression of NFKB target genes IL6, CCL2, ICAM1 , and TNFAIP3 in LCC9 cells, as 
well as the basal expression of ICAM1 and TNFAIP3 and the TNFa-induced CCL2 
and TNFAIP3 in MCF-7 cells. COUP-TFII also suppressed the basal expression of 
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the REL and RELA NFKB subunits in LCC9 cells and the TNFa-induced expression 
of NFKB1, REL, and RELB in LCC9. As the NFKB subunits are also downstream 
targets of the NFKB pathway themselves [306-309], this provides further evidence of 
the decreased NFKB activation with COUP-TFII transfection. The correlation 
between COUP-TFII and NFKB target gene and subunit expression was further 
examined through analysis of data from a microarray of gene expression in breast 
tumors from ERa+ breast cancer patients treated with tamoxifen. Consistent with the 
data in Chapter IV, an inverse correlation was found between COUP-TFII and 
ICAM1,IL6, TNFAIP3, NFKB2, REL, RELA, and RELB in the patient samples. This 
suggests that the same trend seen in the breast cancer cells is also true for breast 
cancer patients. 
To further investigate the mechanism of COUP-TFII regulation of NFKB 
activation, the impact of COUP-TFII on NFKB DNA-binding was analyzed through 
EMSA. COUP-TFII suppressed DNA-binding in both an in vitro assay where in vitro 
transcribed/translated COUP-TFII was incubated with nuclear extract from LCC9 
cells treated with TNFa, as well as in an EMSA with nuclear extract from MCF-7 
and LCC9 cells transfected with COUP-TFII. Further, co-immunoprecipitation 
revealed that COUP-TFII interacts with NFKB subunits RelB and NFKB 1. This 
suggests COUP-TFII interaction with NFKB subunits inhibits binding to the NFKB 
RE and decreases NFKB activation. COUP-TFII also inhibited induction of NFKB 
activity by coactivators SRC-1, SRC-3, and CBP, implying that COUP-TFII and 
NFKB compete for these coactivators, a mechanism that has been recently reported 
for COUP-TFII action on other transcription factors [295] . 
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Identification of COUP-TFII as a negative regulator of NFKB activity in 
breast cancer cells provides valuable information about the possible mechanism by 
which COUP-TFII helps prevent the progression to endocrine-resistance. It may 
partly explain the ability of COUP-TFII to increase endocrine sensitivity [116], as 
well as why endocrine-resistant cells (which have lower COUP-TFII expression) have 
induced NFKB activity. These data also point to future use for COUP-TFII as both a 
biomarker as well as a target for the enhancement of endocrine sensitivity. LCC9 
endocrine-resistant cells were found to be more sensitive to treatment with an NFKB 
inhibitor, and showed markedly reduced cell proliferation as compared to MCF-7 
cells. This may be due to their increased dependence on the NFKB pathway for cell 
survival, and may provide a target for therapeutic intervention. 
Chapters III and IV have highlighted the importance of interacting proteins on 
COUP-TFII function. The focus of the experiments described in Chapter V is to 
identify proteins which differentially interact with COUP-TFII upon treatment with 
tamoxifen. Many proteins were identified which could provide a starting point for 
future studies. DAVID analysis was used to identify common themes amongst the 
interacting proteins, including RNA splicing, calmodulin-binding, and A TP-binding. 
As calmodulin was also found in the interacting proteins with EtOH (vehicle control) 
treatment, and verified through co-immunoprecipitation in Chapter V, this could be 
an interesting pathway for further investigation. 
Also in Chapter V, the interaction between COUP-TFII and HSP27 was 
verified through co-immunoprecipitation. Despite reports that HSP27 increase cell 
proliferation and plays an oncogenic role in cancer progression [335-337], reduced 
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HSP27 expression was found with increasing endocrine-resistance. Reduced HSP27 
expression was also present in JIMT -1 trastuzumab-resistant breast cancer cells. 
Conflicting reports have identified HSP27 as both increasing [322,342] and 
decreasing drug resistance [321,324], and the interaction and positive correlation of 
COUP-TFII and HSP27 merits further study. Phosphorylation of HSP27 at Serine 15, 
78, and 82 also plays a role in cellular localization and function [319,325], and has 
not been widely studied in resistance to antiestrogens or other drugs. A correlation of 
HSP27 phosphorylation at Ser82 and drug resistance was not found in the endocrine-
resistant and trastuzumab-resistant cell lines studied in Chapter V, but further studies 
will investigate phosphorylation at other serines. Subcellular localization of HSP27 
in these cell lines will also be examined. 
Overall, this study has provided important new information about the many 
roles of COUP-TFII in breast cancer and confirmed the importance of COUP-TFII-, 
interacting proteins to its cellular function. Further investigation of the mechanisms 
responsible for the ability of COUP-TFII to enhance endocrine sensitivity is crucial 
for its use as a biomarker or therapeutic target. Identification of biomarkers to enable 
detection of patients who would respond favorably to endocrine therapy would be of 
great use, as would discovery of a target to reduce endocrine resistance in patients. 
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APPENDIX I - SUPPLEMENTARY MATERIAL 
Methods SI 
Transient transfection with pCOUP-TFII-FLAG. MCF-7 cells, purchased from 
ATCC, and used at passages <10, were transiently transfected with 2 I-1g pCOUP-
TFII-FLAG using the P-20 program of the Amaxa Nucleofection System. Cells were 
'serum-starved' in phenol red-free IMEM supplemented with 5% dextran coated 
charcoal stripped FBS (DCC-FBS) for 24 h before treatment with vehicle control 
ethanol (EtOH) for 2 h as indicated in the experimental design (Fig. 1). 
Protein identification by multidimensional protein identification technology 
(MudPIT). Proteins eluted from the FLAG-affinity gel (Fig. 1) were digested by 
trypsin, desalted with C18 spin columns, dried by speedvac, and fractionated by 
strong cation exchange (SCX). The desalted samples were dissolved with loading 
buffer containing 20% acetonitrile (ACN), 100 mM acetic acid (HAc), and 2 mM 
~Acetate and then loaded on a pre-cleaned SCX cartridge from Michrom 
Bioresources. After washing twice, peptides were eluted stepwise with 20 /-ll of 
HAc~Ac buffers with increasing ionic strength and pH (15 buffers and up to 10 
mM HAcl615 mM NH4Ac, pH 6.5). The SCX fractions were concentrated by 
speedvac and diluted to 7 /-ll with 5% ACN/O.1 % formic acid. 5 /-ll of the samples 
were loaded to CapLC capillary LC system from Waters and peptides in the samples 
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were separated with a 3.5 ~m Symmetry C18 column (75 ~m x 150 mm, Waters). 
MS/MS spectra of the peptides were acquired by Q-TOF mass spectrometer (Waters) in 
data dependent mode. Proteins were identified by comparing MS/MS spectra with 
sequences in Swiss-Prot database by ProteinLynx from Waters. 
Immunofluorescence staining of pCOUP-TFII-FLAG. Cells were grown on 
coverslips, washed with PBS, fixed with cold methanol/acetone 1: 1 for 5 min, and 
washed twice with cold PBS. After blocking with 1% goat serum and 0.3 % Triton X-
100 in PBS for 30 min, primary FLAG antibody (Sigma) was added (1: 300 dilution) for 
1 h. After removing the primary antibody, the cells were stained with secondary anti-
mouse antibody labeled with Zenon ™ Alexa Fluor 488 (Molecular Probes). Cells were 
then incubated with ProLong@ Gold antifade reagent with DAPI (Molecular Probes). 
Images (Fig. SI) were captured using a Zeiss Axiovert200 inverted microscope with a 
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Figure SI: Nuclear localization ofCOUP-TFII in transfected MCF-7 cells. 
A, MCF-7 cells were either non-transfected (control) or transfected with pCOUP-TFII-
FLAG for 48 h. Immunofluorescence staining was performed for FLAG as described in 
Supplementary Materials and Methods. Cells were counterstained with DAPI (blue) to 
image nuclei. The bar is 20 Jlm. Overlap images indicate localization ofCOUP-TFII-
FLAG in the nucleus. B, Western blots of CE (30 Jlg) or NE (10 Jlg) from untransfected 
MCF-7 cells (control) or transfected with pIRES-GFP-la parental vector or pCOUP-
TFII-FLAG with FLAG or ERa (AER320, ThermoFisher) antibodies. The two bands are 
likely due to protein degradation. C, Ponceau S staining shows protein levels. 
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Figure 82: Overexpression of COUP-TFII-FLAG in MCF-7 cells and 
immunocapture ofCOUP-TF-FLAG by the anti-FLAG agarose affinity resin. 
1 FLAG 
A, Briefly, MCF-7 cells were transiently transfected with C-terminal FLAG-tagged 
COUP-TFII or empty vector for 24 h as described in Materials and Methods. WCEs were 
prepared and incubated with EZ view Red ANTI-FLAG M2 Affinity gel (Sigma) for 16 
h. After rinsing, proteins were eluted with serial glycine elutions: 1. 15 min at room 
temperature for proteins associating with immobilized COUP-TFII-FLAG with moderate 
affinity and 2. 5 min at 95°C to elute proteins bound to the immobilized COUP-TFII-
FLAG with high affinity. Imrnunoprecipitating proteins were analyzed by MudPIT. Non-
specific proteins were subtracted from the total interacting proteins to identify proteins 
specifically interacting with COUP-TFII-FLAG. B, 30 Jlg of WCE from LCC9, MCF-7 
and MCF-7 cells transiently transfected with pCOUP-TFII-FLAG were separated by 
SDS-PAGE and western blots were performed for COUP-TFII, FLAG and b-actin. 
Quantitation of the COUP-TFII/~-actin in lanes 2 and 3 indicate a 2-fold increase COUP-
TFII in the transfected cells. TAM-R LCC9 cells served as a negative control, as we 
reported lower COUP-TFII in LCC9 cells compared to parental MCF-7 cells (Riggs et al 
Cancer Res. 66: 10188-98, 2006). Note FLAG signal was only detected in the 
transfected cells (lane 2), indicating specificity. C, 1 mg of protein in WCE from COUP-
TFII-FLAG over-expressing MCF-7 cells was immunocaptured on anti-FLAG agarose 
affinity beads. COUP-TFII and interacting proteins were eluted with 6 M urea. 30Jlg of 
WCE were separated by SDS-PAGE in parallel to 30 Jlg unbound IP supernatant and 
30Jlg eluted protein. COUP-TFII-FLAG-affinity bead binding is confirmed by decreased 
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Figure S3: Testing elution methods for retrieval of COUP-TFII-FLAG. 
- 1 mg ofWCE from MCF-7 cells transfected with pCOUP-TFII-FLAG was 
immunocaptured on the anti-FLAG affinity resin and eluted with sequential glycine 
incubations: 1) 10 or 15 min room temperature (lanes 2 and 4) or 5 min. at 95°C (lanes 3 
and 5) in two different experiments (Exp A or B), as indicated (lanes 2-5). Samples of 
the indicated eluates were separated by SDS-PAGE and immunoblotted using anti-FLAG 
antibody. 20 ~g of the IP supernatant, containing unbound COUP-TFII-FLAG, was run 
in parallel as a control (lane 1). As seen in lane 5, incubation with glycine for 15 min. 
followed by a 5 min. incubation of fresh glycine at 95°C (Exp. B) eluted the most intact 
COUP-TFII-FLAG (-50 kDa). The increased temperature and incubation time of glycine 
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Figure 84: Endogenous nuclear nucleolin-COUP-TFII interaction in MCF-7 cells. 
A, Equal amounts (100 f.lg) of protein of CE and NE from MCF-7 cells were 
imrnunoprecipitated with nucleolin mAB (lanes 3 and 4), mouse (m) IgG (negative 
control for mAB , lanes 5 and 6), COUP-TFII antisera (lanes 7 and 8), or rabbit (r) IgG 
(negative control for IPs using COUP-TFII polyclonal antiserum, lanes 9 and 10), 
followed by western blot for nucleolin and COUP-TFII. 20% (20 f.lg) input NE and CE 
serve as loading controls (lanes 1 and 2). B, The relative amolmt of nucleolin and 
COUP-TFII in the nucleolin IP was plotted relative to expression of each protein in the 
input (set to 100). COUP-TFII in rabbit IgG IPs was not graphed because of the 
contamination of the heavy IgG chain (lanes 7 and 8, COUP-TFII blot). Western blots 
demonstrate that: 1) nucleolin interacts with COUP-TFII in the NE of MCF-7 cells (lane 
7); 2) nucleolin is not IP' ed with rabbit IgG (lanes 9 and 10); 3) more COUP-TFII 
interacts with nucleolin in NE IP' ed with nucleolin antibody than with mouse IgG (lane 3 
versus lane 5). C, MCF-7 cells were treated with EtOH, 10 nM E2, or 100 nM 4-0HT for 
1 h prior to separation of NE and CE. 200 f.lg of NE or CE were IP' ed with polyclonal 
COUP-TFII antibody and imrnunoblotted with a monoclonal antibody (mAE) against 
nucleolin. The blot was stripped and re-probed with mAE against COUP-TFII. D, 10% 
input for NE and CE used in IP in part C. 
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Figure S5: ChIP of COUP-TFII-FLAG on the RARB2 promoter in MCF-7 cells. A, 
Chromatin immunoprecipitation was performed in MCF-7 cells transfected with pIRES-
COUP-TFII-FLAG or empty vector, serum starved for 48 h, and treated with 1 ~ atRA 
for 1 h. Following Q-PCR using primers to the RARB2 promoter as described in 
Materials and Methods, duplicate samples were run on a 2% agarose gel. B, Only EV -
EtOH set to 1. atRA increased COUP-TFII-FLAG binding to the RARB2 promoter 32%. 






























Figure 86: Expression of COUP-TFII and nucleolin in T47D and MCF-7 cells. A, 
WCE (50 J..lg) were Western blotted for COUP-TFII and nuc1eolin expression. The blot 
was stripped and re-probed for ~-actin. B, The ratio of nuc1eolinJ~-actin and COUP-
TFIII~-actin for each cell lines was plotted. These data are the average of 3 separate 
experiments. The lower COUP-TFII expression in T47D agrees with the higher CT 
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Figure 87: Effect of cell treatments on NR2F2 (COUP-TFII) expression in MCF-7 
cells. A, Schematic diagram of transfection and treatment of MCF-7 cells. MCF-7 cells 
were transfected with equal amounts of pT AG2 control vector or pCMV -nucleolin for 24 
h., treated with 10 ~ CRO or ASI411, as indicted for 24 h, and 1 j.lM atRA was added 
for the last 6 h. RNA was harvested and Q-PCR performed. B, NR2F2 values were 
normalized to GAPDH. Values are the average of 6 separate experiments ± SEM. * 
signific. different, p < 0.05 in one way ANOV A followed by Bonferroni multiple 
comparison test. Note that there was no statistical difference between the pT AG+AS 1411 
versus Nucl+AS I411 or ASI411 sample measurements of NR2F2. 
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Figure S8: Neither AS1411 nor CRO inhibit MCF -7 cell viability after 4 d. MCF-7 
cells were treated with the indicated concentrations of AS1411 or CRO and cell viability 
was measured by an MTT assay (A490nm, Promega CellTitre assay). Values are the 
average of 4 determinations ± SEM. 
165 















Figure S9: Oncomine examination of NR2F2 expression in breast tumors. Data 
mining in Oncomine microarray data sets for NR2F2 in breast cancer identified that: A, 
NR2F2 expression is significantly higher in ERa+ breast tumors (p < 0.007). B. NR2F2 
is significantly lower in metastatic breast tumors (p < 0.05). Data are from (van de Vijver 
MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in 
breast cancer. N Engl J Med 2002; 347: 1999-2009). 
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Table SI: Identification of proteins in MCF-7 WCE that non-specifically (NS) 
interact with the anti-FLAG-affinity resin. 
1 mg protein in WCE from EMPTY-FLAG vector-transfected MCF-7 cells was 
incubated with anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 15 min. at 
RT, and subjected to MudPIT peptide identification. Matched number (No) indicates the 
number of sequenced peptides that match the full length protein. Coverage indicates the 
% of the total protein matched. 
Protein name Accession Mass pi Matched Coverage 
~Gll ~Mrl ~N°l ~%l 
Cytoskeletal proteins 
Actin cytoplasm ic 1 P60709 41710 5.4 4 15.5 
Tropomyosin alpha-4 chain P67936 28505 4.7 4 17.3 
Tropomyosin alpha-3 chain P06753 29015 4.8 4 18.1 
Myosin-9 P35579 226392 4.6 4 3.0 
Tropomyosin beta chain P07951 32970 4.7 5 23.6 
Tropomyosin alpha-1 chain P09493 32689 4.7 4 14.8 
Myosin light polypeptide 6 P60660 16788 4.6 3 22.7 
Histones 
Histone H4 P62805 11 229 11.4 3 29.4 
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Table 82: Identification of proteins 'moderately' associated with COUP-TFII in 
MCF-7 cells. 
1 mg protein in WCE from pCOVP-TFII-FLAG transfected, EtOH-treated MCF-7 cells 
was incubated with anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 15 h at 
RT, and subjected to MudPIT peptide identification. Matched number (No) indicates the 
number of sequenced peptides that match the full length protein. Coverage indicates the 
% of the total protein matched. This table excludes proteins that were nonspecifically 
associated with the anti-FLAG affinity gel as summarized in Table Sl. 
Protein name (gene) Accession Mass pi Matched Coverage 
~GIl ~Mrl ~Nol ~%l 
Ribonucleoproteins 
Heterogeneous nuclear 
Q14103 22435 11.3 2 10.2 ribonucleoprotein DO 
Histones 
Histone H2A.Z POCOS5 13414 10.9 2 7.9-16 
Core histone macro-H2A.1 075367 39445 10.1 2 5.4 
Histone H1.5 P16401 22435 11.3 3 10.2 
Histone H1 .2 P16403 21221 11.3 3 10.8 
Histone H3.1 P68431 15263 11.3 2 10.4 
Other Proteins 
Heat Shock 70 kOa protein B 
P48741 26890 7.6 3 16.2 (HSPA7) 
Heat Shock 70 kOa protein 1 
P08107 70009 5.6 3 6.2 HSP70 (HSPA1A) 
Chromobox Protein Homolog 3 
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Figure S10. Expression of COUP-TFII in transfected MCF -7 and LCC9 cells. 
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 
48 h and treated with 10 ng/ml TNFa for 6 h before preparing whole cell extracts. 
Expression of COUP-TFII was analyzed by western blot and compared to ~-actin control. 
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Figure Sl1. Specificity of protein complex binding to NFKB-RE DNA probe. 
Full EMSA picture from Fig. 6B. 25 j.lg NE prepared from MCF-7 and LCC9 cells 
transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 48 h and treated with TNFa 
for 6 h was incubated with e2PJNFKB-RE DNA probe +/- lOOX cold unlabeled DNA 
probe for 1 h to perform EMSA. Binding to e2PJNFKB-RE DNA probe is inhibited by 
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Figure S12. BMS-345541 inhibits NFKB activity in MCF-7 and LCC9 cells. 
MCF-7 and LCC9 cells were semm-starved for 24 h before being transfected with a 
NFKB luciferase reporter for 48 h and treated with various concentrations of an NFKB 
inhibitor, BMS-345541 +/- 10 ng/ml TNFa for 6 h. Dualluciferase assay was performed 
to verify that the BMS-345541 inhibited NFKB activity at these concentrations. Firefly 
luciferase values are shown relative to pGL4-hRluc-TK Renilla (Promega). Note higher 
NFKB activity in semm-starved MCF-7 cells as compared to normal media (Figure 1). 
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